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There is increasing evidence of prodromal manifestation of neuropsychiatric symptoms in
a variety of neurodegenerative diseases such as Parkinson’s disease (PD) and Huntington’s
disease (HD). These affective symptoms may be observed many years before the core
diagnostic symptoms of the neurological condition. It is becoming more apparent that
depression is a significant modifying factor of the trajectory of disease progression and
even treatment outcomes. It is therefore crucial that we understand the potential patho-
physiologies related to the primary condition, which could contribute to the development
of depression. The hypothalamic–pituitary–adrenal (HPA)-axis is a key neuroendocrine sig-
naling system involved in physiological homeostasis and stress response. Disturbances of
this system lead to severe hormonal imbalances, and the majority of such patients also
present with behavioral deficits and/or mood disorders. Dysregulation of the HPA-axis is
also strongly implicated in the pathology of major depressive disorder. Consistent with this,
antidepressant drugs, such as the selective serotonin reuptake inhibitors have been shown
to alter HPA-axis activity. In this review, we will summarize the current state of knowledge
regarding HPA-axis pathology in Alzheimer’s, PD and HD, differentiating between prodro-
mal and later stages of disease progression when evidence is available. Both clinical and
preclinical evidence will be examined, but we highlight animal model studies as being par-
ticularly useful for uncovering novel mechanisms of pathology related to co-morbid mood
disorders. Finally, we purpose utilizing the preclinical evidence to better inform prospective,
intervention studies.
Keywords: HPA-axis, depression, cortisol, dexamethasone, Alzheimer’s disease, Parkinsonian disorders, Hunting-
ton’s disease, BDNFVal66Met
OVERVIEW
INTRODUCTION
Mental illness has emerged to become one of the most significant
chronic health issues at the present time. The management of the
wide spectrum of psychiatric conditions presents as a great socioe-
conomic challenge. It is a multi-tiered problem ranging from
early diagnosis and effective treatment of patients, counseling,
and support for families to government-borne infrastructure and
healthcare costs. Major depressive disorders (MDDs) are the third
highest contributor to the global burden of disease (1, 2) and MDD
is recognizably the most publicly discussed mental health condi-
tion. The combination of population growth and ever-increasing
numbers of an aged population means that the absolute number of
individuals suffering from depression is on a sharp upward trend
(2, 3). A recent study conducted by the Centres for Disease Control
and Prevention in the USA reported that of 235,067 adults exam-
ined, 9% were found to have symptoms of depression with 3.4%
suffering from MDD. In Australia alone, an estimated one mil-
lion adults suffer depression, with approximately one in six people
expected to experience depression at least once in their lifetime
(Beyondblue). Despite this high reported prevalence, the actual
number of depression sufferers most likely exceeds estimates and
predictions (4). Current research efforts have focused on increas-
ing awareness for depression, better diagnostic approaches, and
more effective treatment strategies. It is a leading cause of prema-
ture death in the US along with the likes of cardiovascular disease
and cancer (5). It is estimated that over the next 20 years, depres-
sion will become the second leading cause of disability worldwide
and the number one cause of disability in high-income nations,
even discounting secondary diseases associated with depression (2,
3, 6–9). Depression is a major predictive factor for suicide (9) as it
correlates with greater number of suicide attempts and increased
lethality (10, 11). Research finds that 48% of depression patients
have suicide ideation (12), and there is a significant correlation
between number of depressive episodes and suicide attempts (13).
It has been reported that compared with suicide attempters, suicide
completers were more likely to be suffering from MDD (14, 15).
Depressed mood, in its own right, is a specific symptom of
MDD (in accordance with DSM-5). The characteristic state of
lowered mood and an aversion for participating in everyday activ-
ities collectively affects a person’s thoughts, feelings and wellbeing.
One prevailing philosophy argues that depression is a result of the
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inability of the brain to make suitable adaptations in response to
stressors due to impaired or inadequate neural plasticity (16–18).
However, the pathophysiological factors underlying depression are
numerous. The collective evidence suggests that all accounts of
depression are unlikely to be associated with a single causative
factor. Instead, it appears that depression manifests as a results of
complex interplay between genetic (e.g., susceptibility genes) and
non-genetic risk factors (e.g., traumatic life events).
One important consideration for medical practitioners and pri-
mary care providers is that while major depression comprises a
major health concern in its own right, it is certainly not beyond
appearing as a symptom of other health conditions. Depression
is often reported as a co-morbid symptom in other neurological
disorders, such as schizophrenia (19), Alzheimer’s diseases (AD)
(20), Parkinson’s diseases (PD) (21, 22), and Huntington’s dis-
eases (HD) (23–25). It is also present with major diseases, such as
type II diabetes (26, 27), cardiovascular disease (6, 28), and alco-
hol withdrawal syndrome (29). In the context of cardiovascular
disease, the presence of depression is a significant risk factor for
worse outcomes and symptom severity [reviewed in Ref. (30–32)].
Thus, early recognition that the patient is exhibiting symptoms of
depression should be followed-up with appropriate treatment so
as to achieve a more wholesome recovery for the patient. To-date,
there have been several publications discussing the implications of
co-morbid depression relevant to these latter-mentioned health
conditions, so this present review will focus on the neurological
conditions.
Public education and advocacy for a better understanding of
depression have had some success in pulling aside the veil of mis-
understanding and prejudice associated with this mental health
condition. While the social perception of this debilitating disorder
has improved for the better, depression as a co-morbid symptom
of neurodegenerative diseases, in particular AD, PD, and HD, has
suffered neglect from the scientific and medical societies. Neurode-
generation is the umbrella term for loss of neuronal structure or
functions. Depression is prevalent in all three diseases but has long
been regarded by many as a collateral symptom caused by natural
reaction to the decline of faculties, knowledge of diagnosis, or side
effects of medications. Otherwise, it has been overshadowed by
other symptoms, such motor and cognitive abnormalities. How-
ever, recent studies have provided evidence that depression within
neurodegenerative disorders is possibly linked to the pathologies
characteristic of these diseases. Better understanding of the etiol-
ogy of depression in the context of the specific neurodegenerative
disease will help us improve on current approaches to clinical
treatment. Ultimately, it would lead to more effective and targeted
treatments, which will undoubtedly benefit the patients and their
families.
THE ROLE OF THE HPA-AXIS IN DEPRESSION
The hypothalamic–pituitary–adrenal (HPA)-axis is the major
endocrine system that regulates the physiological response to stress
and as a result drive how an organism might adapt its own behavior
or environment in order to accommodate that stress. The HPA-axis
is well established to exert an influence over a wide variety of phys-
iological processes including digestion, immune response, emo-
tions, energy metabolism, and sexual behavior. The high degree of
conservation in HPA-axis genes across species, even in the earli-
est vertebrates, is testament to its evolutionary significance (33).
To briefly outline the HPA-axis circuit, the perception of a stress
(e.g., threat to the life of the organism) initiates a signal within
the paraventricular nucleus (PVN) of the hypothalamus. Neurons
in the PVN synthesize and secrete corticotrophin-releasing hor-
mone (CRH), which is shunted through the hypophyseal portal
system and binds to specific receptors in the anterior pituitary
(adenohypophysis). This then stimulates the synthesis and release
of adrenocorticotropic hormone (ACTH) from the anterior pitu-
itary, which is released into the circulatory system. Ultimately,
ACTH triggers the synthesis and secretion of glucocorticoids
(GCs; cortisol in humans, corticosterone in rodents) from the
adrenal cortex (34). Activity of the HPA-axis may be altered with
natural aging (35), but salivary (36) and plasma (37) cortisol con-
centrations are greater in individuals suffering from depression.
Treatment with selective serotonin reuptake inhibitors (SSRIs)
significantly decreases the concentration of urinary free cortisol
levels (37). Separate reports have also demonstrated that HPA-axis
activity is altered in AD (38), PD (39), and HD (40). Under-
standing HPA-axis pathology specific to these neurodegenerative
conditions might shed light on why there is a higher incidence of
co-morbid depression.
The HPA-axis exists as a self-regulatory physiological system
responsive to negative GC feedback. GCs signal through two recep-
tors, namely, the GC receptor (GR) and mineralocorticoid receptor
(MR). The MR is a promiscuous receptor that binds, in addition
to GCs, mineralocorticoids, aldosterone, deoxycorticosterone, and
progesterone. However, in comparison, the affinity of GCs to MR
is 10 times that of GR (41–43). The continuous MR activation by
baseline levels of circulating GC is required for survival of dentate
granule neurons (44) as well as having a plethora of functions,
such as the regulation of electrolytes, blood pressure, and sympa-
thetic drive (45, 46). GR, on the other hand, has low affinity for
GC and is only active when GC levels are high, as in following the
experience of a major stressor. The GR is involved in mobiliza-
tion of energy resources and facilitates the termination of stress
response and GC production, as part of the negative feedback
loop to regulate HPA-axis activity (47). GR is highly expressed in
the hippocampus, hypothalamus (48), and the prefrontal cortex
(49). It acts as a ligand-activated transcription factor upon activa-
tion to control metabolism for fight-or-flight responses as well as
inhibiting further GC production by suppressing HPA-axis acti-
vation (50, 51). Alterations of GC signaling play a major causal
role in the development of depression (52, 53). These could be
caused by subtle changes to GR function as a result of functional
polymorphisms (54). The expression patterns of GR and/or MR
are altered across different brain regions in AD (55) and PD (56).
Given the important roles of GR and MR in regulating HPA-axis
activity, it is therefore reasonable to speculate that a pathological
alteration of GR/MR expression in those neurodegenerative dis-
eases could contribute to the greater incidence of depression in
these specific patient populations through a common modality,
namely dysregulation of the HPA-axis.
Seminally, Carroll (57) found dysfunction of the HPA-axis in
depression patients (57), giving a biological target to researchers
who have since discovered the umbrella-like effects of this
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overarching endocrine system in relation to depression and psy-
chiatric disorders in general. Clinically, as observed in Cushing’s
syndrome, hyperactivity of the HPA-axis is highly correlated with
significant increases in psychopathology, especially depression
(58–60). Dorn et al. found in their study that 66% of Cush-
ing’s patients exhibited psychopathology, consisting mainly of
atypical and major depression as well as anxiety disorder and
suicide ideation. Three months following treatment for hypercor-
tisolemia, this dropped significantly to 54% and further decreased
to 24% 12 months after correction (61). These suggested a direct
causative link between elevated cortisol and psychopathology.
Treatment of hypercortisolemia also reverses the hippocampal
atrophy that is evident in Cushing’s disease (62). In clinical depres-
sion, hyperactivity of the HPA-axis is the most replicated biological
state found (63, 64).
The dexamethasone suppression test (DST) is a method to
evaluate HPA-axis function. It is based on the administration of
dexamethasone (DEX),a synthetic GC that binds with high affinity
to GR. This simulates the molecular cascade for negative feedback
with the end result being a suppression of cortisol release. Blood
is collected from the subject to determine their cortisol suppres-
sion response with the expectation that most individuals would
have diminished serum/plasma cortisol levels. The DST has been
used extensively in depression research, and non-suppression is
observed with high frequency for individuals with major depres-
sion (65, 66) as well as other related conditions, such as bipolar
disorder (67). It is important to note that DST non-suppression is
also observed in a portion of the non-depressed population. The
DST can be adapted to allow a more specific examination of the
other key points of the HPA-axis. Several hours after the initial
dose of DEX, CRH, or adrenocorticotrophin hormone (ACTH) is
administered to the subjects prior to blood collection. The DEX–
CRH combination allows evaluation of pituitary function with
the cortisol response as the primary read-out, although ACTH
levels can also be quantified (68, 69). In recovered patients, their
DEX–CRH response does not differ compared to healthy con-
trols (70). However, despite numerous patient–control studies and
the suggestion that DEX–CRH is a more accurate approach to
study HPA-axis activity (71), there is still an argument that the
DEX–CRH test has yet to be fully validated as a clinical test for
depression (72). In comparison, the DEX–ACTH combination is
a directed examination of adrenal cortex function because ACTH
interacts specifically with the adrenal cortical cells that respond
by synthesizing and releasing cortisol. However, the take-up of
this test has been very limited (73). Similarly, focusing on the
neurological diseases, there are very few studies using the DST
or DEX–CRH/ACTH tests (Tables 1–3). This is probably due to
the fact that these tests are often used to probe the physiological
aspects of depression symptoms, the latter of which tends not to be
a priority for the treating physician. However, it is hoped that this
will change given the mounting evidence that depression might be
a significant modifier of disease process.
OTHER MOLECULAR PATHOLOGIES LINKED WITH HPA-AXIS
DYSFUNCTION
Tight regulation of GC levels is essential as prolonged exposure to
high concentrations alters numerous cellular processes potentially
damaging the brain. Neuronal activity is directly influenced by
GC levels through its regulation of the alpha subunit of the active
Na+ channel (74). Cell turnover in the hippocampus is gener-
ally inhibited by higher levels of GCs, and numerous studies have
found decreased numbers of proliferating cells and reduced cell
survival in the dentate gyrus after administration of corticosterone
in rodents (75–77). Chronic exposure to high levels of GCs is
also linked with apoptosis, particularly of the GR-expressing neu-
rons in the hippocampus (78–81). Administration of high doses
of GCs led to atrophy in the hippocampus of rats (82) and mon-
keys (83), as well as neuronal atrophy (84) and volume reduction
in the prefrontal cortex (85). These effects are attributable to the
regulatory role of GR in increasing the ratio of pro- versus anti-
apoptotic molecules as demonstrated in the rat hippocampus (86).
GR activation also induces translocation of the tumor suppres-
sor protein to the nucleus thereby increasing its transcriptional
activity (87).
Depression is notoriously plethoric in its various aspects
of pathology. Numerous molecular signaling systems, such as
monoamines like serotonin, noradrenalin, and dopamine are
found to be dysregulated (88–90). Inflammatory cytokines are
abnormally increased in depressive disorder (91). Brain-derived
neurotrophic factor (BDNF), an essential neurotrophin, is report-
edly diminished in depressed patients but recovered in patients
receiving treatment (92). Separately, altered BDNF levels and sig-
naling through the TrkB receptor have been implicated in the
pathophysiology of PTSD (93). Interlaced with all the afore-
mentioned factors is the HPA-axis which influences and is in
turn influenced by monoamines (94–97), cytokines (98–100), and
BDNF/TrkB signaling (101).
RATIONALE FOR THIS REVIEW
Separately, there are good bodies of evidence supporting a higher
incidence of depression and HPA-axis dysfunction in AD, PD,
and HD. However, whether the disease-related HPA-axis dysfunc-
tion accounts in some part for the co-morbid depression remains
unclear. It will be important to consolidate our knowledge of how
disease-specific events bring about HPA-axis dysfunction through
molecular pathology, and how the consequentially altered levels
of circulating GCs (especially in the brain) might impact on dis-
ease progression and severity of symptoms. In this review, we will
summarize the current literature regarding the prevalence of co-
morbid depression in AD, PD, and HD. We will then examine the
evidence of HPA-axis dysfunction in the three neurodegenerative
diseases, drawing not only on the findings of clinical studies but
also preclinical evidence where available. The DST will be dis-
cussed as a potentially reliable clinical tool to identify patients
manifesting HPA-axis dysfunction who might then be at risk for
developing depression. We will also consider more recent evidence
of how GCs might change the processing or interactions of key
disease-related proteins (e.g., Aβ, htt) and how this might affect
disease progression.
A discussion of the similarities and differences underlying the
system and its regulation and influences upon factors intimately
linked with depression in the various milieus of AD, PD, and HD
may prompt new avenues through which to tackle depression in
neurodegenerative diseases.
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Table 1 | Summary of clinical and preclinical evidence for HPA-axis pathology in Alzheimer’s disease.
Condition Measurable Directionality
of change
Clinical/
preclinical
Reference
AD
Cortisol levels
Increased
Clinical (123, 126, 137, 143, 502, 503)
Basal serum/ Preclinical TgCRND8 APP: (182); Aged male 3xTg-AD: (504)
plasma
Unchanged
Clinical (125, 134, 505, 506)
Preclinical Young 3xTg-AD transgenic line (male and female): (133, 507)
Increased
Clinical (55, 146)CSF
Preclinical No preclinical evidence to-date
Suppression
Clinical (122, 508, 509)
Preclinical apoE-/- and ApoE ε3 transgenic lines: (510)Dexamethasone suppression test
Nonsuppression
Clinical (124, 125, 506, 511, 512)
Preclinical ApoE ε4 transgenic line: (510)
Clinical
Hypersensitive cortisol response: (125, 502, 512);
DEX-CRH challenge: hypo-response: (512)CRH challenge
Preclinical No preclinical evidence to-date
Clinical Hypersensitive cortisol response: (135);
no change: (136)ACTH challenge
Preclinical No preclinical evidence to-date
Note the contradictory clinical evidence for the dexamethasone suppression test and limited evidence from animal model studies. Absence of preclinical evidence
is noted for several measures.
Table 2 | Summary of clinical and preclinical evidence for HPA-axis pathology in Parkinson’s disease.
Condition Measurable Directionality
of change
Clinical/
preclinical
Reference
PD Clinical (280, 281, 286)Increased
Preclinical TgS/MPTP pharmacological model: (513)
Basal serum/ Clinical (287, 291)Cortisol Unchanged
plasma Preclinical 8-OH-DPAT/l-Dopa pharmacological model: (514)levels
Clinical (276, 279)Decreased
Preclinical No preclinical evidence to-date
CSF No data available
Suppression Clinical (39, 508)Dexamethasone suppression test
Non-suppression Clinical (286)
Clinical No clinical evidence to-date
CRH challenge Preclinical No preclinical evidence to-date
Clinical Normal (cross-sectional study with no healthy controls): (515)ACTH challenge
Preclinical No preclinical evidence to-date
Note the unavailability of clinical data regarding CSF cortisol levels and responses to CRH or ATCH challenges. Also note the relative lack of depth to the preclinical
evidence here compared to AD and HD.
Table 3 | Summary of cortisol changes detected in Huntington’s disease and other functional tests of HPA-axis regulation.
Condition Measurable Directionality
of change
Clinical/
preclinical
Reference
HD Clinical (40, 399, 400, 407)Increased
Preclinical 6-week R6/2 transgenic line: (402)
Basal serum/ Clinical Single cohort of female patients: (383)Cortisol Unchanged
plasma Preclinical 12-week R6/1 transgenic line: (412)levels
Decreased Clinical Specific to non-depressed patients: (403)
CSF No data available
Suppression Clinical (399, 410)
Preclinical (412)Dexamethasone suppression test
Non-suppression –
Clinical Greater cortisol peak: (399)CRH challenge
Preclinical Normative corticosterone peak in DEX-CRH challenge: (412)
Clinical No clinical data availableACTH challenge
Preclinical Elevated corticosterone peak in DEX-ACTH challenge: (412)
Note the absence of preclinical evidence from other rodent models of HD besides R6 transgenic mouse lines.
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DEPRESSION IN ALZHEIMER’S DISEASE
Alzheimer’s disease is the leading cause of dementia and its etiology
comprises a complex interaction between multiple genetic risk
factors and environmental (lifestyle) modifiers (102, 103). There
are two broad classifications of AD – early and late-onset. Late-
onset AD is generally linked with aging; although recent studies
have uncovered the involvement of significant genetic influences
too (104). In addition to specific impairments of memory recall
as part of a broad dementia spectrum, psychiatric symptoms are
also a prominent feature of this disease.
Symptoms of MDD are reported more frequently in AD
patients compared to the wider healthy population. The presence
of depression significantly influences AD brain pathology (105),
including increased accumulation of amyloid protein in the brain
(106). Vascular risk factors and altered neurotransmitter signal-
ing have also been put forth as causative factors for co-morbid
depression [reviewed by Chi et al. (107)]. However, the precise
pathophysiology that accounts for the behavioral symptoms has
not been determined. Interestingly, both independent studies and
meta-analyses have reported that depression is a significant risk
factor for developing AD (and other forms of dementia) (108,109).
Consistent with that, recent re-examination of the data from the
Framingham Heart study found that depression was a significant
risk factor for dementia and AD in older males and females within
that study population (110). For some, these psychiatric changes
may develop prior to cognitive decline. In a recent review, Belleville
et al. suggested that the presence of neuropsychiatric symptoms
including depression and anxiety should be included as significant
factors in a multi-factorial predictive model for the earliest signs
of AD (111). There is evidence that depression co-morbidity is
associated with a greater extent and progression of disease pathol-
ogy, such as increased neurofibrillary tangle load (112) and poorer
rate of cognitive decline (113). It is quite concerning that a recent
meta-analysis revealed a lack of efficacy of typical antidepressant
medications for treating AD patients for co-morbid depression
(114). The molecular and cellular effects of antidepressant com-
pounds are well understood, so further research should be invested
into understanding why there is this apparent lack of efficacy of
these drugs to treat the depressive symptoms. The current evidence
also indicates that effective treatment of co-morbid depression
with SSRIs is not associated with an improvement of cognitive
symptoms (115). That implies that the cognitive aspects of AD
symptomatology are separate from depression pathology, but it
is still possible that the benefits of antidepressant treatment may
manifest in other markers of pathology. It is worth noting that
MDD is defined by a range of symptoms, and further research is
still required to parse out the specific aspects of MDD that may
relate more specifically to AD pathology (116). To that effect, one
recent study has suggested the specific behavioral symptoms may
differ for AD and mild cognitive impairment (117).
Studies of preclinical models of AD have comprehensively
demonstrated that depressive symptoms are almost certainly part
of the wider pathological phenotype of the disease. Studies of
rodent behavior are unlikely to recapitulate the psychosocial
aspects of AD, so any changes in the behavioral phenotype are
more than likely attributable to in vivo pathophysiology. A single
intracerebroventricular (i.c.v.) injection of soluble oligomers of
the amyloid-β peptide elicits pro-depressive behavioral changes
in mice after 24 h (118). That effect on behavior was not only
acute, but also persisted for 8 days (perhaps linked to protein
turnover). Treated mice displayed greater immobility time on the
forced-swim test, a well-validated behavioral test used to quan-
tify behavioral despair. Mice also exhibited reduced exploratory
movement (hypolocomotion) and lower preference for sucrose-
sweetened solution (anhedonia – another key symptom of depres-
sive disorder). Treatment with the SSRI fluoxetine was capable
of rescuing the forced-swim test phenotype, although its effect
in the other tests was not established in this study. Previously,
another study had administered the Aβ(1–40) peptide i.c.v. and
also reported that treated mice recorded increased FST immo-
bility times that were rescued by acute desipramine injection
(119). A separate study using a similar approach also reported
increased immobility time on the tail-suspension test, and that
behavioral response was blocked by pre-treatment of the neu-
ropeptide NPY (120). In future, it would be interesting to investi-
gate using preclinical models whether drugs commonly prescribed
to AD patients to treat the cognitive symptoms of dementia (e.g.,
acetylcholinesterase inhibitors or memantine) are also effective in
modifying depression-related behaviors.
HPA-AXIS PATHOPHYSIOLOGY MEDIATES DEPRESSION IN AD
The collective evidence strongly indicates that activity of the HPA-
axis is dysregulated in AD. The presence of the pathological soluble
form of Aβ alone appears to be the key event sufficient to deregulate
central control of HPA-axis activity. In rats, the single action of an
acute i.c.v. injection of Aβ(25–35) is sufficient to induce HPA-axis
hyperactivity (121). Therefore, in humans, the early accumulation
of the pathological forms of Aβ is likely to contribute to over-
all dysregulation of the HPA-axis. This is supported by evidence
that early-stage AD patients have increased basal plasma cortisol
levels (122, 123) and decreased sensitivity to low-dose DEX sup-
pression (124, 125). In mild to moderate AD, serum cortisol levels
remain significantly elevated together with DHEA and androstene-
dione levels, while estradiol levels were unaffected in females (126).
The majority of investigations to-date have tended to focus on
the central premise that there is hyperactivity of the HPA-axis in
AD without more closely examining HPA-axis pathology beyond
the hypothalamus. Few studies have explored beyond measuring
cortisol as a direct reflection of HPA-axis activity. There are numer-
ous targets one could quantify as a measure of HPA-axis activity
including hypothalamic neuropeptides and androgens. This is one
aspect of the AD research field that could be improved upon.
One of the earliest knowledge of HPA-axis dysfunction in AD
was from the correlation of cerebrospinal fluid (CSF) CRF-like
immunoreactivity with the patients’ neuropsychological ratings
(127) and severity of dementia (128). However, no significant dif-
ference in serum CRF levels was reported for AD patients and
health controls (129). Moreover, CRF changes are likely to be cen-
tral, not peripheral, because subsequent closer inspections of post
mortem AD brains revealed decrease in both free and complexed
forms of CRF in a variety of discrete brain regions (130). These
suggested that in AD, either hypothalamic CRF-secreting neurons
are hypoactive or there is an active modulation to reduce CRF tone
in response to HPA-axis hyperactivity. There is some evidence of
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AD pathology impacting on CRF-immunopositive neurons within
the PVN of the hypothalamus (131, 132). The human post mortem
data are complemented by findings of early diminishment of CRF
gene expression in PVN neurons in presymptomatic 3xTg-AD
mice (133). Interestingly, the downregulation of CRF gene expres-
sion could be a homeostatic response to HPA-axis hyperactivity
because AD patients administered a dose of CRF have a signif-
icantly greater cortisol response compared to healthy controls
(134). At a glance, the progressive pathology within the hypothala-
mus has not been thoroughly examined in the AD brain. Similarly,
the evidence of AD-associated adrenal dysfunction is few and even
contradicting. One study had reported adrenal hypersensitivity
after finding significantly greater cortisol response to ACTH stim-
ulation (135), but this was contradicted by a second study that
instead claimed abnormal androgen secretion (136).
Alzheimer’s disease patients have significantly higher levels of
cortisol with an exaggerated diurnal rhythm (134, 137). Consistent
with that, cortisol levels quantified from ventricular CSF of pre-
senile AD patients post mortem are significantly higher compared
to age-matched controls (138). The directionality of that change is
identical to what is observed in MDD (as mentioned in Introduc-
tion). Recent studies by Peavy et al. suggest that the initial signs
of dementia-associated cognitive changes are reflective of HPA-
axis dysregulation. Using a series of multivariate logistic regression
analyses to qualify the self-reported complaints of memory deficits
by cognitively normal elderly volunteers, Peavy et al. reported that
both the average post-peak cortisol level and the cortisol awak-
ening response correlate with the number of memory-related
complaints (139). However, dysregulation of the HPA-axis itself
does not appear to directly contribute to the worsening of dis-
ease symptoms because those same measures of cortisol were
not associated with the progression from mild cognitive impair-
ment to dementia (140). Instead, it is highly probable that other
environmental modifiers, such as a persistent exposure to stress,
influence the rate of cognitive decline (141). The impact of stress
on cognitive function is well established. It is not surprising that
HPA-axis dysfunction can cause cognitive deficits because the hip-
pocampus, which is central to memory and cognition [reviewed
by Opitz (142)], is also highly dense in GR expression and closely
linked to depression pathology. Interestingly, a study by Murialdo
et al. examining the relationship between hippocampal dysfunc-
tion and HPA-axis found that dehydroepiandrosterone (DHEAS)
levels were a better correlate than cortisol levels for impaired
hippocampal perfusion measured using SPECT imaging (143).
Perhaps future studies of hippocampal dysfunction as a struc-
tural surrogate of cognitive deficits and depressive disorder should
explore the inclusion of both cortisol and DHEAS levels as part of
their predictive modeling.
Serum and plasma cortisol measurements have previously been
suggested as a reliable biomarker for AD (144, 145). Additionally,
the well-described e4 risk variant of apolipoprotein (APOe4) risk
genotype further distinguishes a subpopulation with significantly
higher plasma cortisol levels (55, 146, 147), a likely reflection of the
role that the APO protein has in the normal regulation of GC syn-
thesis (148). However, it has also been suggested that the APOe4
genotype is predictive of central nervous system (CSF) cortisol
levels but not peripheral (serum) cortisol levels (149). There is
a current lack of information regarding the accuracy of central
(compared to peripheral) cortisol levels as a biomarker for AD,
partly attributable to the preference and ease of collecting blood
samples from patients compared to lumbar puncture. However, in
spite of the procedural challenges, it is important that we estab-
lish which biosample more accurately reflects APOe4-associated
cortisol levels, and resolution of this matter can only be achieved
by future studies utilizing large patient cohorts. Knowing how
the APO genotype influences HPA-axis dysfunction will also be
important for understanding how this genotype modulates cogni-
tion. Although Peavy et al. reported that the well-described APOe4
could not account for the greater number of memory-related com-
plaints in their study (139), a separate study has claimed that the
APOe4 is associated with worse baseline memory performance
and an accelerated rate of memory decline (150). It is possible that
this inconsistency reflects the reliance on self-reported data as well
as the use of different patient questionnaires, so the findings of
these studies cannot be regarded as conclusive until successfully
replicated by independent research groups.
Genetic heterogeneity presents as an enormous hurdle to
population-based clinical studies seeking to uncover subtle pheno-
typic differences. Large cohort studies will be required to account
for the likely involvement of multiple AD risk genes acting as
“genetic triggers” for HPA-axis dysfunction and depression. In this
regard, preclinical studies of rodent models that are genetically
homogeneous have tended to be more useful for understand-
ing the roles of specific AD risk genes in the disease phenotype.
Young asymptomatic 3- to 4-month-old 3xTg-AD mice possess-
ing the PS1M146V, APPswe, and tauP301L transgenes (151) have
normal basal levels of corticosterone (133). While hippocampal
dysfunction is already evident in these young animals (152), the
depressive behaviors only emerge as the mice age to 20 months
(153). A similar discordance has been reported in a separate trans-
genic mouse model which over-expresses human APP wherein
impaired hippocampus neurogenesis was evident months prior to
the emergence of depressive behavior (154). For both transgenic
lines, whether the depressive phenotype emerges concurrent with
HPA-axis dysfunction is unknown. Future studies should exam-
ine this so as to generate preclinical evidence that dysfunction of
the HPA-axis is causative of the depressive symptoms. In addi-
tion, such a study would uncover any potential relationship of
those AD risk genes with HPA-axis dysfunction and the depressive
symptoms.
Studies of rodent models of AD have yet to thoroughly inves-
tigate the potential of environmental enrichment, an experimen-
tal paradigm well established to exert anxiolytic, anti-depressive,
and pro-cognitive benefits [see review by Nithianantharajah and
Hannan (155)]. A recent study demonstrated that environmental
enrichment rescues the cognitive deficits in the Tg2576 transgenic
mouse model of AD by reducing levels of tau phosphorylation
and rescuing the deficit in hippocampal neurogenesis during dis-
ease progression (156). Similarly, despite strong evidence that
physical activity is a significant modifier for dementia-related
cognitive deficits [reviewed by Pang and Hannan (157)], few stud-
ies have examined the potential to rescue depressive behavioral
changes in the context of AD (and more broadly, dementia).
Thus, investigating the anti-depressive effects of environmental
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enrichment and physical activity on the various transgenic mouse
models of AD would appear to be a worthwhile endeavor.
MOLECULAR PATHOLOGIES OF THE HPA-AXIS IN AD
Multiple genetic risk factors implicated in MDD could be mod-
ulating the risk for co-morbid depression within the AD popula-
tion. The combination of two or more gene× gene interactions
wherein each gene polymorphism subtly alters a given signal-
ing pathway culminates in a significant neurochemical imbalance
and the higher risk for developing depression. Genetic polymor-
phisms of a number of serotonin receptors well established to be
involved with MDD pathology have been independently linked
to the increased likelihood of AD patients developing symptoms
of depressive disorder (158). A separate genetic risk factor, the
BDNF Val66Met polymorphism, has been reported to stratify AD
patients with and without co-morbid depression (159). The BDNF
Vall66Met functional polymorphism was also implicated in a more
recent cross-sectional study wherein sex was an additional factor of
investigation (160). BDNF signals downstream via the TrkB recep-
tor and selective receptor agonists such as 7,8-dihdyroxyflavone
are well established to exert anti-depressive effects (161, 162).
Several studies have established the neuroprotective effects of 7,8-
dihdyroxyflavone on cognitive deficits in mouse models of AD
(163–166). However, its effectiveness in rescuing the depressive
phenotype has yet to be investigated. Arlt et al. reported that there
was an increased risk of having MDD for female AD patients with
the BDNF Val66Met polymorphism (160). This was one of a few
studies that had identified gender as a significant modifier for
disease symptoms. Further investigations should be conducted to
examine potential sex-specific differences in neuronal pathology
within the brain regions that are known to regulate emotionality.
Three other significant genetic polymorphisms were also identified
in that study of which only the FKBP5 polymorphism was signifi-
cant for their entire cohort. FKBP5 has been strongly implicated in
depression pathology (167–169), so future studies should investi-
gate whether FKBP5 polymorphisms are also significant modifiers
for depression within the AD patient population. For the purpose
of this section, we will specifically focus on molecular pathology
within the HPA-axis attributed to genetic risk factors for AD and
how this might impact on depressive symptomatology.
Having the knowledge of the longitudinal progressive molecu-
lar pathology of an AD brain paired to the precise moment at which
specific disease symptoms manifest would be ideal. Unfortunately,
it is practically impossible to conduct clinical studies to identify
the earliest molecular pathology in AD brains and track their nat-
ural progression. This can be achieved with preclinical models
with the one caveat that current rodent models of AD are based on
infrequent/rare genetic mutations identified in the human popula-
tion. Thus, there is somewhat limited construct validity. Recently,
using a transcriptomics approach, a profiling study of brains col-
lected from APP/PS1 transgenic mice at different ages revealed that
the earliest detectable disease-related changes (as opposed to age-
related changes) are the downregulation of HPA-axis-associated
genes linked to metabolism, depression, and appetite (170). This
finding strongly supports the hypothesis that dysregulation of the
HPA-axis is a key pathological event in early AD. In fact, it could
be the seed event for other aspects of disease pathology. It also
provides a pathophysiological basis for the higher incidence of co-
morbid depression in AD, especially as one of the earliest predictive
symptom of AD. However, a major short-coming of that study was
that it did not examine depression-associated behavioral changes
in the mice at those same ages. Progressive behavioral changes
have previously been described in the APP/PS1 transgenic mouse
model (171) but there has yet to be a study focusing on depression-
related behaviors. A longitudinal study of that nature that tracks
the development of behavior symptoms correlated to molecular
pathology in specific brain regions would provide great insight
into development of depression in AD. However, returning to the
current limitations of preclinical models of AD, the heterogenetic
nature of this disease means that those findings would be limited
to APP/PS1 mutations, and subsequent validation studies using
other genetic models would still be required.
While there is clinical evidence that the APO genotype might
predict hippocampal-dependent cognitive deficits, a key question
that remains unresolved is whether APOe4 similarly predicts the
likelihood of an AD patient developing depressive symptoms. At
present, this is unclear. Locke et al. claim that this risk genotype
does not affect the incidence and the progression of depression
symptoms (172) but this lone study still requires independent
replication in larger cohorts. A close relationship between the
APOe4 risk genotype and depression in the context of AD was
uncovered by a recent functional MRI study (173). It was reported
that the APOe4 risk genotype and presence of geriatric depres-
sion were significant co-variables in accounting for changes in
cortico-hippocampal connectivity resulting in a greater risk for
developing AD. That is, having depression worsens the extent of
structural pathology in the AD brain. However, with recent reports
of novel AD-associated gene loci (104, 174), the likelihood of a
predictive model for depression in AD based on a single geneo-
type is slim. That notion is supported by the knowledge that the
extent of APOe4-linked HPA-axis dysfunction is further subject
to additional genetic modifiers, e.g., TOMM40, a variable-length
polymorphism that exists in linkage disequilibrium with APOE
(175, 176). In other words, co-morbid depression might manifest
differently in specific subpopulations of AD patients, requiring
them to carry a specific combination of risk genes. As evidence
of this, de Quervain et al. (177) reported that a rare haplotype in
the 5’ regulatory region of 11beta-hydroxysteroid dehydrogenase
type 1 (HSD11B1) was associated with increased risk for sporadic
AD (177). The functional consequences of altered HSD11B1 on
overall HPA-axis activity in the presence of Aβ pathology have yet
to be studied. Thus, future studies will have to discard a mono-
genic associative approach and expand to consider the influence
of multiple genes in order to accurately determine the incidence
of co-morbid depression in AD.
The GR is the essential regulator of the HPA-axis negative
feedback system, and several SNPs have been linked to MDD
pathophysiology, metabolic changes, and dysregulation of stress
response [reviewed by Manenschijn et al. (178)]. Polymorphisms
of the MR are also implicated but to a lesser extent [reviewed
by Spijker and van Rossum (179)]. Evidence that early-stage AD
patients have increased basal plasma cortisol levels (122, 123)
suggests failure of the normal GR-mediated homeostatic feed-
back mechanism to maintain normative cortisol levels. Also, AD
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patients have decreased sensitivity to low-dose DEX suppression
(124, 125). In mild to moderate AD, a progressive degeneration
of HPA-axis is observed as serum cortisol levels remain signifi-
cantly elevated together with DHEA and androstenedione levels,
while estradiol levels were unaffected in females (126). One study
reported that the GC-binding domain of GRα is not altered in AD,
but other regions of the gene have not been investigated (180),
nor has the GRβ isoform been examined. A study of post mortem
brain samples by Gil-Bea et al. (55) state that the APOε4 genotype
correlated with an abnormal increase in MR but not GR expres-
sion in BA10 of the frontal cortex (55). (Note that GR expression
was significantly decreased regardless of APOe4 genotype for all
AD brains.) The cause of an imbalance in GR/MR ratios is very
likely to be the sheer presence of soluble Aβ protein. A single i.c.v.
injection of Aβ(25–35) administered to rats is sufficient to cause
an imbalance in GR/MR ratios in the hypothalamus, hippocam-
pus, and amygdala (121). As a consequence, animals developed
generalized dysregulation of the HPA-axis with increased CRF,
ACTH, and cortisol levels. The behavioral profile of these animals
also changed for the worse, with higher levels of anxiety as well
as impaired short- and long-term memory (181). Extrapolating
that data, in humans, it is likely that the early accumulation of the
pathological soluble form of Aβ causes HPA-axis dysregulation by
disrupting GR/MR-mediated homeostasis.
Young 3- to 4-month-old 3xTg-AD mice have increased hip-
pocampal levels of MR and GR mRNA concurrent with Aβ accu-
mulation (133). The increase in gene expression of both GR and
MR is consistent with the post mortem findings of Gil-Bea et al.
(55). There was also increased GR gene expression in the PVN
of the hypothalamus; however, there was a marked absence of
detectable Aβ pathology in the PVN that would be suggestive
of a more generalized dysregulation of the HPA-axis originating
at the hypothalamus. It would therefore be interesting to probe
GR and MR expression levels in human post mortem samples.
Consistent with increased GR expression was the concomitant
decrease of CRH gene expression in PVN neurons. Previously,
another study of the TgCRND8 APP transgenic mouse model
had reported a similar progressive dysregulation of the HPA-axis,
although the dysfunction was specifically attributed to adreno-
cortical hyperactivity that was detected in male prior to female
Tg mice (182). As mentioned previously, subtle differences in
the manifestation of depression and HPA-axis pathophysiology
within the AD population have yet to be thoroughly investigated.
That sex differences are also observed in preclinical models surely
provides the impetus for further research, possibly starting with
an examination of adrenocortical function. At the present time, a
thorough examination for evidence of Aβ accumulation in adrenal
cortical cells has yet to be conducted. It is possible that chronic
adrenocortical hyperactivity is a feature of early AD, and the HPA-
axis maintains homeostasis by downregulating GR and CRH. In
a study by Murialdo (122), AD subjects showed higher cortisol
and cortisol/DHEAS ratios and lower DHEAS levels in compari-
son with controls following the DST (183). Interestingly, 32% of
AD subjects showed cortisol levels above the conventional cut-
off of 140 nmol/L (DST non-supressors), despite no significant
differences in the clinical parameters compared to DST suppres-
sor patients. Both ACTH and cortisol levels were not different in
suppressor and non-suppressor patients, but DHEAS levels were
significantly lower in non-suppressor cases. This initial evidence is
suggestive of adrenal specific pathology as another factor in AD-
associated HPA-axis dysfunction. The precise temporal sequence
of HPA-axis pathology is yet to be determined, but could poten-
tially uncover novel biomarkers of early AD, or more specifi-
cally identify individuals with AD who are at risk of developing
co-morbid depression.
GLUCOCORTICOID-MEDIATED EFFECTS ON AD MOLECULAR
PATHOLOGY
Thus far, we have discussed co-morbid depression as a behavioral
manifestation of HPA-axis dysfunction (likely) caused by the accu-
mulation of Aβ. Here, we will summarize the current evidence that
the consequential hypercortisolemia in turn negatively modulates
AD-related disease processes. Taken together, it emphasizes the
importance of addressing HPA-axis dysfunction and the timely
treatment of depression in AD.
Neuronal, astrocytic and mitochondrial metabolic distur-
bances (184–186) are consistently reported in various models of
AD, and thus appear key to the disease process. Independently,
those disturbances in cell energetics are similar to those reported
in MDD (187–189), and each has been separately shown to be
possible outcomes for chronic or excessive GC exposure (190–
195). Thus, it is possible that many pathological features of AD are
directly caused by the accumulated effects of increased GC levels.
This is one aspect of AD pathophysiology that has yet to be thor-
oughly investigated. In this section, we will review the evidence
that elevated cortisol levels as a result of HPA-axis dysfunction
could significantly modify AD-related pathology and potentially
hasten disease progression.
Perturbation of normal cell metabolism within the hippocam-
pal network is another likely cause of the cognitive deficits and
pro-depressive behaviors in AD. GC-induced metabolic changes
are partially mediated by a key metabolic enzyme, adenosine
monophosphate-activated protein kinase (AMPK). AMPK activ-
ity is crucial for normal functioning neuronal networks (196), and
its enzymatic activity is prone to modulation by GC levels (197).
A recent study used the AMPK inhibitor, Compound C, to correct
the deficits in hippocampal LTP and LTD recorded from APP/PS1
transgenic mice (198). Examining the potential for Compound
C treatment to correct HPA-axis dysfunction and rescue the pro-
depressive phenotype of this particular AD transgenic mouse line
would be an interesting follow-up. It should be stated that a distur-
bance of cellular metabolism is not a novel concept in the context
of AD pathology. For example, abnormal homocysteine metabo-
lism resulting in hyperhomocysteinemia is one aspect that has been
heavily investigated. In their recent examination of post-mortem
brains, Hooshmand et al. reported that elevated plasma homocys-
teine levels were significantly associated with the accumulation of
neurofibrillary tangles and Aβ accumulation (199). That finding is
supported by preclinical evidence associating hyperhomocysteine-
mia with the development of Aβ-related cerebral angiopathy (200).
Independently, in rats, restraint stress induces elevated GC levels
and also homocysteine levels (201). Therefore, it is also possible
that abnormal homocysteine levels in AD are yet another con-
sequence of HPA-axis dysregulation. However, the use of plasma
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homocysteine levels as a biomarker for co-morbid depression in
AD remains to be validated (202, 203).
In a discussion of GC modification of AD pathology, it is
impossible to ignore the contribution of stress. Given the evi-
dence that HPA-axis dysregulation occurs in the earliest stages of
AD, one could speculate that the further imposition of stress on
an individual afflicted with AD could potentially hasten disease
processes and also be a major factor in the development of depres-
sion [see review of Dong and Csernansky (204)]. A central theme
of many studies in this area is understanding how the experience
of stress impacts on in vivo Aβ processing. In rats, both expo-
sure to chronic unpredictable stress and GC treatment resulted
in the misprocessing and accumulation of Aβ levels, as well as
hyperphosphorylation of tau protein, in the frontal cortex and
hippocampus (205, 206). This impact of GCs on Aβ accumula-
tion is also reproduced in vitro with rat neuronal PC12 cells (207).
Those molecular pathologies were associated with the emergence
of anxiety behavior and impairment of spatial memory in the
Morris water maze. Mouse studies have also demonstrated that
stress acting through the HPA-axis compounds, the accumulation
of AD-relevant proteins. In the Tg1276 mouse model of amyloid
precursor protein (APP) pathology, a single acute bout of restraint
stress increased interstitial fluid Aβ load (208). The concentration
of soluble extracellular Aβ is highly relevant to disease pathol-
ogy. It is well accepted that the soluble form of the protein that
exerts a neurotoxic effect, with one mode of mechanism possibly
involving neuronal microRNAs (209). Curiously, there is a dearth
of literature examining the progressive and cumulative effects of
chronic mild stress. It is unrealistic to extrapolate data collected of
a rodent that has been exposed to a single bout of stress to humans
who experience a lifetime stress, each of varying degree. While it
does not diminish the importance of establishing the pathological
consequences of a single stressful event on Aβ levels in an in vivo
model, the logical follow-up experiment would be to study the
accumulated effects of chronic subthreshold stress, e.g., using the
well-established paradigm of chronic mild stress. An experiment
such as this would more closely model the persistent exposure to
stress by humans and enable us to better understand how chronic
stress impacts on AD disease processes.
In rats, manipulating the concentration of circulating corticos-
terone alters the severity of Aβ-induced neurodegeneration (210).
The potential for stress to change soluble Aβ concentrations in
humans has yet examined. This could be investigated through a
longitudinal study to correlate the accumulation of stressful events
with soluble Aβ load. Such a study could further examine the
effect of manifesting depression, as well as the influence of risk
genotypes. Interestingly, the stress-triggered increase in Aβ con-
centration can be inhibited by CRF receptor antagonists but not
by corticosterone (208). That implies that hypothalamic and/or
pituitary neuropeptides have the ability to directly regulate the
production of Aβ protein. This finding opens up the possibility of
novel targets within the HPA-axis for pharmacotherapy with the
aim of minimizing Aβ build-up.
In addition to accelerating the accumulation of Aβ, other AD-
related disease processes likely to be influenced by stress and
abnormally elevated cortisol levels include the build-up of beta-
amyloid plaques and insoluble tau inclusions (211–213). The
impact of stress is not limited to neurons and also extends to
astrocytes, which respond by upregulating APP and BACE1 (214).
It is interesting and important to note that chronic corticosterone
administration does not mimic the pathological effects of restraint
stress (213). That suggests a dissociation and the existence of a
more complex relationship between the broader cortical regions
that regulate negative emotionality associated with the experience
of stress, and the HPA-axis itself. Despite the challenges of dis-
covering selective compounds and targeting precise brain regions,
the HPA-axis remains an attractive physiological system to target
for anti-depressive and possibly AD treatments. One particular
target within the HPA-axis that has emerged is the CRF recep-
tor. For example, in two different transgenic mouse models of
AD, the pre-stress application of a CRF receptor Type 1 (CRFr1)
antagonist prevented the stress-induced accumulation of Aβ, tau
aggregation, neurodegeneration, and memory impairments (213).
In a separate study, reducing CRFr1-singalling normalized the
hypercortisolemia and anxiety phenotype of the APP/hAβ/PS1
knockin mouse model of familial AD (215). These are very promis-
ing outcomes and further investigations of CRFr1 antagonism
would extend to examinations of HPA-axis function, as well as
its anti-depressive potential.
It is reasonable to question why, despite the strong evidence
of GR dysfunction and hypercortisolemia, direct intervention of
GR function has not been adopted as widely available therapeutic
option. It is not as straightforward as attempting to address the
hyperactive response of the HPA-axis through administration of
GR antagonists, e.g., DEX, RU486. Also, multiple side effects have
been revealed from preclinical studies. One study found that while
administering a 5 mg/kg dose of dexamethasone to Tg2576 trans-
genic mice decreased phosphorylation at specific residues of the
tau protein, this also led to an increase in soluble Aβ(1–40) peptide
concentration in the brain, which was associated with mem-
ory impairment (216). In contrast, 3xTg-AD mice treated with
mifepristone (RU486) were found to improve on their cognitive
deficits and have reduced Aβ levels and tau pathologies (217). The
different outcomes of DEX and mifepristone treatments are not
surprising despite being reliant on similar mechanisms of action,
as evident from the studies of other conditions (218). Short-term
treatment with mifepristone is effective in psychotic major depres-
sion (219) but its efficacy for treating co-morbid depression in
AD is less certain (220). Therefore, further studies are required to
probe the potential of early RU486 administration and its dosing
regime as a treatment for depression in AD, as well as to elucidate
other methods of modulating HPA-axis activity with minimal side
effects.
DEPRESSION IN PARKINSON’S DISEASE
Parkinson’s disease is a progressively degenerative neurological
condition and the second most common neurodegenerative dis-
order after AD (221). It is most noted for the obvious motor
abnormalities such as tremor, rigidity, and postural imbalance.
However, non-motor symptoms including depression are com-
monly reported in PD patients (222, 223), prior to the onset
of motor symptoms (22, 224), and with increasing frequency as
the disease progresses (225). For example, disturbances in sleep
and circadian patterns have been reported in newly diagnosed PD
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patients (226). Anhedonia, a lack of interest in novelty and plea-
surable activities, has been hypothesized to be attributable to PD-
related dysregulation of insular cortex activity (227). Schuurman
et al. concluded in a retrospective study that having depression
may induce the subsequent development of PD (228), although
that could perhaps reflect the hastened trajectory of PD processes
in the presence of depression.
The frequency of depression in PD has been cited anywhere
between 2.7 and 70% (229) and this disparity is likely due to
methodological differences. One of the earliest studies of this was
by Mayeux et al. who reported 40% incidence of depression from
49 consecutive patients (230). Consistent with that figure, and
at about the same time, Gotham et al. reviewed 14 studies and
reported a mean frequency of depression of 46% (231). Several
years later, Cummings found a similar level (~40%) in a review of
26 studies (232). More recently, in a Belgian cohort of 1086 PD
patients, 15.6% presented major depressive episodes (233). In a
smaller study of 202 PD patients, Hu et al. found 37.3% prevalence
of depression (234). In contrast, Tandberg et al. concluded that of
the 245 PD patients examined in their study, only 7.7% met the
clinical criteria for MDD, although a further 45.5% were classified
as mildly depressed (dysthymia) (235). Aarsland et al. utilized the
Neuropsychiatric Inventory to screen for a variety of symptoms
and found that 38% of 139 PD patients in Norway had depression
(21). More recently, in a UK study, Schrag et al. reported that 19.6%
of 92 PD patients had moderate to severe depression (236), so that
estimate is likely to be even greater if those with mild depression
symptoms were included. In a Brazilian study, Carod-Artal et al.
found 47% of a cohort of 115 PD patients scored 11 or more on
the Hospital Anxiety and Depression Scale, and concluded that
this is a main determinant of quality of life for patients (237).
Although the use of different instruments to diagnose depression
between studies makes it difficult to compare figures, it is a rea-
sonable conclusion that depression is more prevalent within the
PD community than the general population.
Depression is often not identified and treated early in PD (234,
238). Mutations in the parkin (PARK2) gene are risk factors for
early onset PD and confer higher risk for depression (239). There
seems to be a missed opportunity to treat this symptom early
in the disease, especially since there is no apparent PD-related
inefficacy of treatment with common antidepressant drugs (240,
241). While there has been one study linking the presence of
depression with abnormal gait (225), there is no strong evidence
to suggest that depression significantly impacts the rate of pro-
gression of the motor symptoms or age of onset of the disease
(unlike for AD as discussed in the previous section). However,
PD patients with depression are reported to have greater sever-
ity of illness as rated by the Unified PD Rating Scale, and also
present with other co-morbidities such as anxiety and memory
problems (242). Increased apathy, itself one of the key diagnostic
features of depression, has been linked specifically with a greater
decline in cognitive performance of drug-naïve PD patients with-
out depression (243). That finding suggests that apathy should be
regarded as an independent neuropsychiatric feature of PD and
be excluded as one of the diagnostic criteria for depression for PD
patients. Furthermore, it could be more closely related to cogni-
tive impairment and revealing of hippocampal dysfunction rather
than the development of depression. To further support this disso-
ciation of apathy from the symptoms of co-morbid depression, it
had previously been suggested that treating depressive PD patients
with SSRIs could in fact worsen their apathy scores (244). Further
research is required to resolve the pathological basis of apathy and
its relation to other symptoms of PD.
Since memory impairments and depression are closely associ-
ated with deficits in hippocampal function, this is one region of the
brain that deserves closer scrutiny for the purposes of diagnosis or
treatment. This is supported by a recent MR-imaging study that
uncovered a significant negative correlation of severity of depres-
sion (Beck depression index scores) and bilateral hippocampus
volume (245). In addition, a negative correlation also existed for
amygdala volume. Together, it suggests that extrastriatal structural
pathology accounts for the non-motor symptoms of PD. The find-
ings of this study could be used as a basis for a future longitudinal
study which tracks the progression of structural pathology in PD
patients with and without depression. Armed with that informa-
tion, it would then be possible to use the regression of hippocampal
(and amygdala volume) as a predictor for the patient developing
depression. Such an approach is not novel, as the rate of hippocam-
pal volume change has previously been used as a predictor of mild
cognitive impairment and dementia (246). Subsequently, profiling
the changes to hippocampal volume could be used as a quantitative
measure of treatment efficacy for interventions targeting cognitive
and depressive symptoms in PD.
Interestingly, other personality traits closely associated with
depression, such as neuroticism, have also been suggested as poten-
tial risk traits for developing depression in PD (247). Recently,
depression was found to be the most important factor associ-
ated with suicidal ideation in PD (248–250). This is a serious
psychological aspect of PD facing physicians and caregivers but
one which could potentially be lessened through timely treatment
of the depressive symptoms. Currently, the true extent to which
manifesting depression alters the trajectory and severity of PD
symptoms is not conclusive. However, given some evidence that
specific symptoms might worsen in tandem with depression, it will
be important to identify and understand the subtle differences in
pathology related to the presence of depression in PD.
The use of animal models of PD to demonstrate a link between
disease pathology and the manifestation of depression in PD has
been somewhat limited. Most sufferers of PD have idiopathic PD,
but ~15% of PD patients have a first degree relative with the dis-
ease, which suggests some degree of heritability (251). Several
genes have been identified as familial risk genes for PD includ-
ing α-synuclein gene (252, 253). There are conflicting reports of
the behavioral phenotype of the A53T transgenic mouse model
of PD (containing the human A53T α-synuclein associated with
an autosomal dominant PD). One study found that these mice
exhibited increased levels of anxiety and progressive cognitive
deficits in addition to motor impairment (254). However, there
have also been several studies reporting that overexpression of
A53T α-synuclein results in reduced anxiety and hyperactivity
(255–257). Currently, a thorough examination of a depression-
related behavioral phenotype related to α-synuclein overexpres-
sion has yet to been reported. Interestingly, A53T transgenic mice
have impaired hippocampal neurogenesis, which is corrected by
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chronic administration of the SSRI fluoxetine (258). However, that
study did not examine treatment effects on a possible depression
phenotype of that transgenic line. That remains a critical aspect
of the A53T model to investigate because fluoxetine failed to cor-
rect the pro-depressive behaviors in the rat 6-OHDA model of PD
(259). By comparison, transgenic mice lacking the CD157/BST1
gene (a risk locus in PD) do not develop motor deficits, but display
behavioral responses indicative of increased depressive behavior
(increased immobility times in the tail-suspension and forced-
swim tests), increased anxiety and decreased preference for novel
social interactions (260). The difference in behavioral phenotypes
of these two distinct transgenic mouse models of PD suggests that
specific genetic risk factors may be linked to a greater likelihood of
developing depression in PD. This intriguing possibility has yet to
be examined within a clinical population, and a preliminary ret-
rospective examination of the currently available databases could
uncover evidence of this.
Besides genetic risk factors, there is evidence that the primary
pathological features of PD itself are sufficient to give rise to
a depression phenotype. Rats treated with 6-OHDA to mimic
the selective cell death of dopaminergic neurons in the stria-
tum recorded greater immobility time in the forced-swim test
for depressive-like behavior (261). However, that result could
be simply explained by the impairment to the animals’ swim-
ming ability. Consistent with that, one recent imaging study had
reported that un-medicated PD patients with depression have
lower 18F-fluorodopa uptake in the striatum compared to the
patient group without depression, suggesting a greater degree of
dopamine dysfunction within that brain structure (262). Rest-
ing state fMRI has also been used to show that PD patients with
depression have increased neural activity in the orbitofrontal area
but reduced connectivity of the prefrontal-limbic neuronal net-
work (263). These initial findings are the basis for further studies,
which aim to identify novel imaging-based biomarkers of depres-
sion in PD. Uncovering the genetic risk factors and mechanisms
underlying the development of depression in PD will be impor-
tant for the development of more effective treatments targeting the
non-motor symptoms of PD. In the next section, we will examine
the evidence and focus on pathology the HPA-axis as a common
mechanism to co-morbid depression in PD.
DOPAMINERGIC DYSREGULATION IS CENTRAL TO HPA-AXIS
PATHOPHYSIOLOGY IN PD
The primary pathophysiology of PD relates to the abnormal accu-
mulation of α-synuclein and formation of Lewy bodies in the brain
(264), with good evidence that neuronal dysfunction occurs prior
to cell death (265). However, whether Lewy bodies are causative
or protective of cell death remains controversial [see reviews by
Obeso et al. (266) and Schulz-Schaeffer (267)]. Despite the broad
presence of Lewy bodies in cortical and limbic structures, there
appears to be selective vulnerability and death of dopamine-
secreting cells in the substantia nigra pars compacta (SNc) (268,
269). It is therefore reasonable to speculate that the presence of
Lewy bodies could be a reliable predictor of the specific brains
regions or physiological systems which are impacted upon in PD.
Interestingly, selective vulnerability is also observed in the
hypothalamus wherein the neurosecretory cells of the PVN in
the hypothalamus remain relatively free of Lewy body formation
(270). At present, it is unclear why these neurons are capable of
preventing the abnormal aggregation of α-synuclein. The extent
to which the normal activity of CRF-immunopositive secretory
neurons is impacted in PD is unknown due to a lack of stud-
ies. No recent studies have examined the status of CRF secretion
in the PD brain and the literature is limited to one study from
decades ago reporting of a reduction in CRF-like immunoreactiv-
ity post mortem neocortical PD brain tissue (271), and another
which examined correlations of several neuropeptides including
CRF in the CSF of idiopathic PD patients but without compar-
ing actual concentrations to the control group (272). However,
regardless of that future studies find, the cause of any hypothala-
mic pathology currently appears to be independent of α-synuclein.
This is evident from a study of the 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) model of Parkinsonism which models
selective dopaminergic cell death in the substantia nigra (273). In
this study by Huang and Lee, targeted ablation of dopaminergic
neurons in a separate brain region was sufficient to cause selective
reductions of CRF-positive neurons in the PVN (and the central
nucleus of the amygdala). That suggests that the survival of hypo-
thalamic CRF neurons is regulated by dopaminergic pathways.
Therefore, studies of dopamine-based interventions (e.g., l-Dopa
replacement) could consider central measurements of CRF as an
additional marker of treatment efficacy.
In contrast, the presence of Lewy bodies has been very recently
confirmed in the posterior pituitary lobe (274), which is involved
in the storage and secretion of antidiuretic hormone and oxy-
tocin. The extent of pathology within the anterior pituitary is
unclear which is unfortunate since the anterior lobe is where the
ACTH-secretory neurons are located and is of specific relevance to
this review. However, PD-related dopaminergic deficits are likely
to disrupt normal pituitary function and ACTH secretion since
the expression of proopiomelanocortin (POMC; the precursor of
ACTH; the other being melanocycle-stimulating hormone, MSH)
is directly regulated by the dopamine D2 receptor (275). In support
of this, plasma ACTH levels of untreated idiopathic PD patients
are significantly lower compared to healthy controls (276), consis-
tent with the diminishment of dopaminergic signaling in the PD
brain. Understanding how pituitary dysfunction could be an addi-
tional modulator of disease progression and symptom severity will
warrant further research.
Compared to the available evidence of central HPA-axis pathol-
ogy, evidence of peripheral pathology is scarce. Lewy bodies are
also detected been detected in the adrenal gland, as well as the
peripheral autonomic nervous system, including the heart and
GI tract (277). Whether the accumulation of Lewy bodies directly
impacts on adrenal function (for both adrenal cortex and medulla)
is unknown at present. The collective evidence indicates that there
is wide-spread dysregulation of the HPA-axis across multiple levels
in PD. This is likely to underlie the high incidence of co-morbid
depression in this disease. The progressive accumulation of HPA-
axis pathology is unknown and will require further research. That
knowledge could then inform us about how HPA-axis dysfunction
influences the progression of PD symptoms, both motor and non-
motor. For example, it has been proposed that targeting POMC
expression could be a feasible therapeutic option in PD in future
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(278). A targeted intervention to correct or minimize HPA-axis
dysfunction could prove to be highly effective in treating depres-
sion, in combination with more the more standard antidepressant
medications.
While it is well regarded that ACTH and cortisol levels are
altered in PD patients, there are conflicting reports of the direc-
tionality of the changes. Early studies had reported reduced levels
of plasma ACTH and cortisol in untreated PD patients (276, 279).
However, in a 24-h profiling study of plasma collected from 12
patients, Hartmann et al. found higher cortisol concentrations in
PD patients, which they attributed to greater adrenal gland burst
activity (280), concurrent with significantly diminished diurnal
variation of cortisol levels. Similarly, elevated serum cortisol levels
were reported in a larger collective study of idiopathic and non-
idiopathic PD patients compared to controls (281). It is important
to note that cortisol concentrations measured from saliva samples
do not reflect any signs of pathology (282) and this should be a
key consideration in the design of future clinical studies. While the
inconsistencies between previous plasma profiling studies could be
attributed to age, progression of disease or drug treatment, salivary
cortisol levels appear to be unaffected by levodopa or dopamine
agonist drug treatments (283), and do not correlate with dura-
tion of the disease and motor symptoms (282). Interestingly, one
study reported that salivary cortisol levels could predict which PD
patients were more likely to engage in risky behavior (284) and this
could be an important consideration in the context of cognitive
deficits or suicide ideation. The collective evidence supports the
occurrence of a dysregulation of HPA-axis activity in PD based on
abnormal cortisol levels, and the challenge at present is to identify
the precise molecular pathology and develop effective treatment
approaches.
The DST has previously been employed to demonstrate alter-
ations in HPA-axis feedback signaling in PD. One early study
stratified a small group of patients by the presence of depres-
sion and reported that PD patients with depression were more
likely to be DST non-suppressors (285). Rabey et al. reported that
a significant proportion of idiopathic PD patients were DST non-
suppressors (17 of 32 patients; 53%) and had higher basal levels
of cortisol and ACTH compared to healthy age-matched con-
trols (20% non-suppressors) (286). That study also found that
the proportion of non-suppressors was not altered after strat-
ification of the patient group for dementia, suggesting that in
PD, HPA-axis pathology is associated with co-morbid depres-
sion, not dementia. More recently, in a study of 11 PD patients,
it was reported that all patients showed DEX suppression of
serum cortisol levels (39). Interestingly, and as a demonstra-
tion of a potential link between cortisol levels and depression
co-morbidity, those PD patients were provided with subthala-
mic nucleus deep brain stimulation over a period of 6 months,
which led to improvement of depression symptoms correlat-
ing with reduced 24-h mean cortisol levels. Surprisingly, stud-
ies to-date have been limited to use the DST in isolation and
have yet to attempt the DST in combination with CRH/ACTH
application. However, these appear to be of low priority now
because of growing evidence that HPA-axis dysregulation in PD is
more reflective of disturbed central neurotransmission (discussed
below).
There is increasing evidence to suggest that it is the broader PD
pathology that impacts on HPA-axis activity. Volpi et al. compared
the incremental response of ACTH and cortisol to administration
of CRH and the non-specific serotonin receptor agonist fenflu-
ramine in 10 PD patients who did not differ in basal ACTH/cortisol
levels compared to controls (287). They reported that while CRH
elicited similar ACTH/cortisol elevations in all subjects demon-
strating intact functional response of the pituitary and adrenal
glands, PD patients were non-responsive to fenfluramine admin-
istration. That indicated that serotonergic control of pituitary-
adrenal response was disrupted; but it is still not clear whether
the reported disturbance is due to impaired pituitary response to
serotonergic signals or a loss of serotonergic regulation of hypo-
thalamic CRH secretion. Substance P is well established to play
a central role in the selective degeneration of dopaminergic neu-
rons (288), and PD patients also exhibit an abnormal blunting
of their ACTH/cortisol response to Substance P infusion (289).
Administration of the opioid antagonist naloxone also elicits sig-
nificantly blunted ACTH and cortisol responses in PD patients
(290), but this impaired response has shown to be rescued after
1 year of levodopa/benserazide treatment (291). The successful
treatment indicates that HPA-axis dysregulation in PD is partly
due to disrupted opioid receptor signaling as a result of the loss of
central dopaminergic neurotransmission in the PD-affected brain.
While levodopa administration is known to acutely reduce corti-
sol release in patients (292, 293), the chronic effects of l-Dopa
treatment on HPA-axis functionality have not been thoroughly
investigated. It will be important to understand whether a par-
tial benefit of long-term impact of chronic l-Dopa treatment is
normalization of HPA-axis function and possibly preventing the
manifestation of depression.
MOLECULAR PATHOLOGIES POTENTIALLY IMPACTING ON HPA-AXIS
IN PD
Compared to AD, there are comparatively fewer studies of the
molecular pathology within the HPA-axis in PD. It is only very
recently that imaging studies have reported volumetric changes
and disrupted neurocircuitry of brain regions linked to emotional-
ity and depression pathology, such as cerebral cortex and amygdala
(245, 294–296). However, there is an absence of studies that crit-
ically examine HPA-axis function in PD. An initial study could
examine the expression patterns of key signaling molecules within
the HPA-axis in human post mortem tissue, e.g., visualization
of CRF-immunopositive neurons in the PVN or even quantifi-
cation of CRF mRNA levels in tissue samples. Such information
is crucial in order to establish the progressive sequence of mol-
ecular pathologies of the HPA-axis in PD patients in relation to
the development of depression. For this section, we will initiate
discussion of the molecular pathologies by examining the hypoth-
esized role of genetic polymorphisms with established associations
with depression (e.g., dopamine D2 receptor, GR, and BDNF). We
will also make mention of other factors that impact on HPA-axis
function such as pro-inflammatory cytokines.
We will first consider the investigations of the dopamine D2
receptor polymorphism and its influence on PD pathology because
dopaminergic dysregulation is at the core of PD pathology and the
receptor plays a crucial role in the normal regulation of HPA-axis
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activity. Carriers of the A1 allele of the Taq1A drd2 polymorphism
have lower levels of D2 receptor binding (297) and this is impli-
cated in depression symptomatology (298). Interestingly, this gene
polymorphism does not appear to be a significant genetic modifier
of depression on its own. Several studies have suggested that the
Taq1A polymorphism acts through interaction with other genetic
factors including the BDNF Val66Met polymorphism (299, 300).
Within the PD population, it has been reported that the Taq1A
drd2 polymorphism does not influence treatment efficacy (301)
but confers risk for PD that varies depending on ethnicity (302).
Homozygous non-Hispanic whites having increased risk of PD
compared to homozygous wild-type carriers. That is in contrast to
African-Americans who are homozygous carriers having reduced
risk of developing PD. Ethnicity-specific modification of PD risk is
not unique and has also been reported for other genetic polymor-
phisms (discussed below). Presently, it is not known whether the
Taq1A drd2 polymorphism is sufficient to differentiate between
depressed and non-depressed PD patients, and this should be a
follow-up study for the future. Dopamine D2 receptor regulation
of pituitary function and ACTH synthesis could potentially be
impacted upon so physiological measurements of this should be
taken.
Another monoamine-related polymorphism that is closely
linked to major depression resides within the promoter region of
the serotonin transporter gene (5HTTLPR), resulting in reduced
expression of the serotonin transporter and dampened serotonin-
ergic tone (303–305). This polymorphism is a risk factor for
co-morbid depression in PD with patients bearing the short allele
of the 5HTTLPR having significantly higher scores on the Hamil-
ton Depression Scale (306, 307). In contrast, depression scores are
not associated with the functional promoter polymorphism of the
monoamine oxidase A (MAOA) gene, thus demonstrating func-
tional relevance of the 5HTTLPR polymorphism to PD-associated
depression. However, the conclusiveness of this association is not
unchallenged (308). In support of the alternative, a radioligand
binding study of 16 post mortem PD brains found no difference
in serotonin transporter binding associated with the 5HTTLPR
polymorphism (309). Validation of the association of this poly-
morphism with the increased risk of depression in PD will require
further investigation utilizing larger sample sizes. Future studies
could also examine whether the 5HTTLPR polymorphism is asso-
ciated with greater severity of depressive symptoms within the PD
population. In addition, taking cortisol and ACTH measurements
should be strongly considered because separate research has found
sex-specific modulation of basal cortisol and ACTH levels by the
5HTTLPR polymorphism (310, 311).
Surprisingly, there have been no studies of the GR polymor-
phisms in the context of PD symptoms or co-morbid depression.
This is one area of research that is in dire need of develop-
ment. The metabolism of other steroids could be involved in
PD pathology, such as Vitamin D (specifically serum levels of
25-hydroxyvitamin D), which is significantly reduced in almost
half of PD patients (312). Higher circulating 25-hydroxyvitamin
D levels are associated with milder disease symptoms (312), while
multiple polymorphisms in the 5’-end of the Vitamin D recep-
tor gene are significant modifiers for age-at-onset of PD (313).
There is no strong evidence to link Vitamin D insufficiency with
HPA-axis dysregulation. However, Vitamin D remains a worthy
candidate for further investigation as a therapeutic option for PD
due to the strong evidence that Vitamin D metabolism exerts a
significant influence over the progression of other neurological
conditions such as multiple sclerosis (314) and supplementa-
tion with omega-3 fatty acids significantly reduces the risk of
depression (315).
There is preclinical evidence to support the need for further
research into the influence of functional polymorphisms of the
GR. Rodent studies have shown that GC signaling is directly
involved with the selective degeneration of dopaminergic neu-
rons. Hence, this highlights the pressing need to fully understand
the contribution of HPA-axis dysfunction and the subsequent
elevation of cortisol levels to progression of PD pathology and
symptoms. In a study to better understand neuroinflammation-
related PD pathology, it was found that GR expression is down-
regulated in the substantia nigra post mortem, and that can be
recapitulated in the MPTP mouse model of dopaminergic dys-
function (56). Closer examination of the MPTP model revealed
that a loss of GR signaling was caused largely by an extensive
nuclear re-localization of GR in activated microglia that caused
an upregulation of pro-inflammatory genes. Taken together with
clinical evidence of altered cortisol levels in PD patients, it is rea-
sonable to speculate that dysregulated HPA-axis activity underlies
the activation of microglia which is pro-inflammatory in the PD
brain. Reactive microglia are found in the hippocampus of PD
brains (316, 317). Interestingly, microglia that express MMP-2, an
key inflammatory enzyme involved in breakdown of extracellular
matrix, are exclusive to the substantia nigra and are not observed
in the hippocampus or cortex (318), which suggests that there is
specificity in the nature of neuroinflammation in the PD brain. It
is also worth noting that TNFα levels are reportedly a distinct vari-
able in accounting for severity of depression in a small cohort of
52 PD patients (as well as accounting for differences in their cog-
nitive performance and sleep disturbances) (319). Recently, it was
found that the TNFα initiates pro-apoptotic signals in dopamine
neurons by inhibiting normal mitochondrial regulation of oxida-
tive stress (320). This body of evidence supports on-going research
into the use of anti-inflammatory and/or anti-oxidant compounds
as additional therapies for PD (321–325).
While the Val66Met polymorphism of BDNF is strongly asso-
ciated with major depression, several independent studies and
meta-analyses have reported that this polymorphism does not
increase the risk for developing PD and severity of symptoms
(326–329). Interestingly, the findings of one meta-analysis study
hint that ethnicity could be a significant modifier for the Val66Met
influence with European, but not Asian, PD patients having a
higher odds ratio of carrying at least one Val allele (330). The
proposal that different genetic modifiers influence risk for PD and
symptom severity is not novel, and the literature is awash with
numerous studies conducted on specific ethnic populations. In
general, the collective evidence supports the involvement of eth-
nic× genotype interactions in PD (331, 332). However, whether
this extends to influence the development of depression by PD
patients is unknown. Interestingly, recent studies have uncov-
ered subtle cognition-related differences in PD patients associated
with the BDNF Met allele (333, 334). Given that depression and
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cognition are intrinsically linked to similar brain structures such
as the hippocampus, extrapolating those findings suggest the like-
lihood that risk or severity of depression could also be influenced
by this common functional polymorphism of BDNF.
GLUCOCORTICOID-MEDIATED EFFECTS ON PD MOLECULAR
PATHOLOGY
As discussed above, disturbances of normal HPA-axis regulation
are observed in PD. What is less clear is how a persistent dys-
regulation of GC levels impacts on PD disease processes. It is
unclear if disease progression is accelerated in a patient mani-
festing co-morbid depression, resulting in poorer prognostic out-
comes. Addressing those issues in a clinical population would be
highly challenging, but possible to attempt with rodent models of
PD. In this section, we will discuss the evidence implicating GCs
in the worsening of PD-related pathology and discuss how these
ultimately lead to an acceleration of symptomatology.
While age has long been considered the most prominent risk
factor for PD (335), it is surprising that there has yet to be a
comprehensive study of the added risk that stress (chronic or
acute) confers. One study of British World War 2 prisoners of
war (exclusively males) did not find any significant difference in
cause of death attributable to PD (336). A more recent prospective
study of almost 10,000 individuals found no significant relation-
ship between psychosocial risk factors and the risk for PD (337).
The authors collated self-reported information about major life
events, economic hardship, social networks, and sleep/exhaustion
levels. Interestingly, only sleep impairment was found to be signif-
icantly associated with PD-related hospitalization, lending further
support to the crucial nature of hypothalamic dysfunction in PD
symptomatology. Given the absence of a substantial body of clin-
ical evidence, there is still great scope for future studies to more
closely examine the potential role of stress in modifying the risk
for developing PD.
Despite the lack of clinical evidence, the collective evidence
from preclinical studies does strongly support the role of stress
and altered GC signaling in influencing the development of disease
pathology and symptoms. There is in vitro evidence implicat-
ing a role of disrupted GR signaling in PD molecular pathology.
Administration of DEX to dopaminergic neurons disrupted GR
signaling, resulting in an upregulation of α-synuclein protein lev-
els (338). GC-mediated upregulation of α-synuclein levels has
also been reported in peripheral blood mononuclear cells cultured
from PD patients (339). Behavioral paradigms well established to
induce physiological and behavioral stress in rodents such as food
deprivation and tail-shock both worsen the severity of the motor
deficits in the 6-OHDA lesion model of PD (340). Consistent with
that, animals exposed to chronic restraint stress prior to the lesion
develop more severe motor symptoms (341). As a demonstra-
tion that stress-induced changes in HPA activity and GC levels
directly influence disease progression, corticosterone supplemen-
tation prior to the 6-OHDA lesion was sufficient to cause worsened
motor symptoms. Furthermore, stressed animals do not display
any level of spontaneous recovery from the lesion unlike unstressed
animals. The GC influence is not specific to the nigrostriatal path-
way and extends to brain regions such as the frontal cortex and hip-
pocampus. Adrenalectomy-induced depletion of corticosterone in
rats results in a dramatic downregulation of parkin protein in hip-
pocampal neurons, and this effect is blocked by replacement of
corticosterone (342). While the definitive experiment has yet to be
conducted, this finding suggests that a stress-induced increase in
GC levels would result in an upregulation of parkin expression and
accelerate abnormal protein accumulation in PD. That hypothe-
sis is supported by a recent report that mouse cortical neurons
in primary culture upregulate parkin mRNA and protein levels
following corticosterone treatment (343).
Negative environmental factors, such as stress, could also exert
direct influence on PD pathogenesis by potentiating inflamma-
tory responses. Stress-induced upregulation of pro-inflammatory
cytokine levels is well established to be mediated by GC signal-
ing. A single intranigral administration of LPS elicited a strong
pro-inflammatory response and death of dopaminergic neurons,
which was more severe in pre-stressed rats (344). As a clear
demonstration of gene× stress interaction, transgenic homozy-
gous knockout mice lacking the parkin gene do not develop
nigrostriatal pathology until challenged with a low dose of LPS
to initiate an inflammatory response (345). Hence, stress could
be exerting a broad negative influence on all parkin-expressing
cells in the brain. Future studies of how stress influences PD
pathology should strongly consider utilizing this parkin knockout
line in combination with stress-eliciting behavioral interventions.
Extending similar research to compare distinct genetic models
of PD could uncover novel gene× stress interactions that mod-
ulate the development of depression in PD, as well as the rate
of disease progression. As mentioned previously, the A53T and
CD157/BST1 transgenic mouse models of PD develop different
behavioral features. It will be interesting to contrast the behav-
ioral and physiological responses of both transgenic lines following
exposure to stressors or corticosterone treatment.
Given that PD pathology involves multiple genetic distur-
bances, it can be expected that new insights into disease pathology
emerge as evidence continues to accumulate. Lately, epigenetic
modifications have emerged as significant molecular events in a
variety of neurological conditions [see reviews by Urdinguio et al.
(346) and Al-Mahdawi et al. (347)] and have been proposed to be
useful for the development of novel therapies (348). DNA methy-
lation is one class of epigenetic modifications, which is gaining
in prominence within the PD research field (349). In a meta-
analysis of PD genome-wide association studies with a pool of
more than 10,000 PD cases, several new risk loci were identified
(350). The methylation pattern at specific CpG dinucleotides in
several genes expressed in the frontal cortex and cerebellum was
significantly modified. Recent studies have reported that differ-
ent brain regions exhibit different patterns of DNA methylation
for specific genes (351). A specific DNA methylation signature of
leukocytic α-synuclein (SNCA) and leucine-rich repeat kinase 2
(LRRK2) has even been proposed as a potential peripheral bio-
marker for PD diagnosis (352). Separate research supports stress
and GC regulation of DNA methylation patterns (353). There have
been numerous studies linking the exposure to stress with altered
DNA methylation profiles of specific genes involved in HPA-axis
regulation, e.g., CRF (354), major depression, and PTSD (355,
356). With the identification of a peripheral methylation-related
biomarker of PD, it will be possible for future studies to explore
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the accumulation of stress and its influence on PD symptoms
and co-morbid depression through longitudinal profiling of DNA
methylation patterns.
DEPRESSION IN HD
Huntington’s disease is a monogenic, progressive neurodegenera-
tive disorder that occurs in approximately 1 in 10,000 people in
most Caucasian populations (357). A CAG trinucleotide repeat
expansion mutation at the N-terminal end of the huntingtin gene
on chromosome 4 leads to an expanded polyglutamine tract in
the huntingtin protein (358, 359). In the post-mortem brains of
HD patients, the presence of intranuclear inclusions containing
N-terminal fragments of the mutant huntingtin protein as well as
other proteins such as ubiquitin have been found (360). Signifi-
cant atrophy is also present, most strikingly in the striatum and
the cerebral cortex, although other areas, such as the hippocampus
and hypothalamus, are also affected (361–364).
Depression is among the most common of the plethora of psy-
chiatric symptoms present in HD, estimated to occur in between
20 and 50% of HD gene carriers (24, 25, 365). Almost 30% of HD
patients attempt suicide at least once and death by suicide in the
HD population is four to eight times that of the general popu-
lation (366, 367). There is a high frequency of suicide ideation,
and the presence of a depressed mood is a significant predictor
to the level of suicide ideation (368, 369). Since the discovery
of the mutation that causes HD and subsequent development of
genetic screening technology, studies have shown that the psycho-
logical burden of discovering one’s HD gene status prior to motor
symptoms manifestation can lead to great stress, which may con-
tribute to the development of depression (370, 371). However, this
mental stress alone has been found to be inadequate to explain
the unusually high pervasion of depression in HD. For example,
depression is estimated to be twice as common in HD as com-
pared to Alzheimer’s patients (372) and PD (373). The suicide
rate in PD is also much lower compared to HD (373, 374). More
tellingly, HD gene carriers who were naïve to their gene status at the
time of assessment and asymptomatic have higher prevalence of
major depression than non-gene carriers who were equally at risk
of inheriting the disease gene (375, 376). Importantly, correlation
was also found between the severity and prevalence of depres-
sion and disease progression (377). A recent study that examined
1993 HD mutation carriers from 15 European countries using the
Unified HD Rating Scale, found that 13% of subjects displayed
moderate to severe level depression. The authors concede that this
might be an under-report as healthy subjects were favorably cho-
sen for the study. Interestingly, only 55% of those with moderate
to severe depression were on antidepressants, suggesting under-
diagnoses of this feature (378). The collective evidence indicates
that depression is endogenous to HD pathophysiology and should
be given special attention, particularly as it appears years before
motor symptom onset.
In the general population, it has long been noted that females
are twice as likely as males to develop clinical depression as
well as generalized anxiety disorder, which is often co-morbid
with depression (379, 380). Despite the extremely high preva-
lence of depression in the HD population, only very recently
have studies examined whether sex differences exist. Investigating
antidepressant usage in prodromal HD patients, Rowe et al. found
that more female HD patients were prescribed antidepressants
than males (381), an indicator of higher rates of depression. That
finding was endorsed by another study reporting that female
HD patients had significantly higher rates of past and current
depression compared to male patients (382). These suggest that a
similar sex difference is reflected in depression in HD. The only
clinical study looking at sex hormones in female HD patients mea-
sured serum testosterone levels but conspicuously not E2 estra-
diol levels (383). Consequently, sex hormones may be involved
in the mediation of depression in HD but this has yet to be
confirmed.
Despite the high incidence of depression and similarities of its
nature to clinical depression, very few studies have examined the
effectiveness of antidepressant treatments in HD patients. The first
such study occurred as recently as 2010, with a small cohort of 17
male HD patients who were given venlafaxine for 4 weeks, which
resulted in alleviation of depression symptoms as measured by the
Beck Depression Inventory and the Hamilton Rating Scale (384). It
should be noted that no controls were used. Two controlled stud-
ies examined the effects of fluoxetine (385) and citalopram (386)
but in non-depressed patients. Both studies found mild benefits
to depression scores (Hamilton Depression Rating Scale). Both
studies had low numbers of subjects (30 and 33 HD patients,
respectively) and because non-depressed subjects were chosen, the
potential benefits of the drugs tested remains unclear. There is
therefore a pressing need for a large cohort, double-blinded, con-
trolled study, ideally with multiple types of antidepressants and
mood stabilizers to establish the best treatment for this serious
symptom of HD.
HYPOTHALAMUS PATHOLOGY IS THE MAIN MEDIATOR OF
DEPRESSION IN HD
Given the good evidence that co-morbid depression is frequent
in HD, many studies have been conducted focusing on describ-
ing the symptoms of depression and treatment. Initially, it was
thought that structural pathology of the hippocampal formation
and shrinkage accounted for the cognitive deficits and depression
in HD, with further speculation that this was caused by deficits
in cell proliferation and neurogenesis [reviewed by Geuze et al.
(387)]. However, post mortem investigations have uncovered no
evidence of changes in the rate of cell proliferation in the sub-
granular zone of the hippocampus associated with HD (388).
Also, there are no further differences between HD cases with
and without mood symptoms. The human data are in contrast
to the significantly reduced levels of hippocampal neurogenesis
in R6/1 transgenic mice (389). However, subsequent studies have
revealed that hippocampal synaptic plasticity is already impaired
during the asymptomatic stages (390, 391). Thus, it is believed
that neuronal dysfunction and disruption of the hippocampal
neurocircuitry are the primary underlying factors for depression
(and cognitive deficits) in HD. More recently, other disparate brain
regions involved in emotional recognition such as the amygdala
have been subject to study. HD patients have a specific impair-
ment in recognizing facial signals of disgust, but the neurological
basis for this is unclear. One study has suggested that the relative
ability of HD patients to successfully recognize facial expressions
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of disgust and happiness correlated to anteroventral insular and
amygdala volumes, respectively (392). Amygdala volume remains
unaffected during the prodromal stages of the disease (393, 394),
but undergoes progressive atrophy that is correlated to the sever-
ity of patients’ emotion-processing deficits (395). Serotonergic
regulation of frontocortical activity plays an important role in
emotional processing and is implicated in depression pathology
(396). There is clinical (397) and preclinical evidence (398) that
expression of a variety of serotonin receptors is reduced in HD,
and these could contribute further to development of depression
in HD. In contrast, less attention has been paid to identifying HPA-
axis pathologies related to HD. There have been surprisingly few
clinical studies, which have explored the more specific hypothesis
that HPA-axis dysfunction could be the main cause of the greater
incidence of depression in HD. In this section, we will summarize
the evidence of HPA-axis pathophysiology in HD, focusing on the
hypothalamus, and consider the clinical and preclinical evidence
of altered neuropeptide signaling.
Similar to clinical depression, the first study to examine the
HPA-axis in a small sample of 10 HD patients found evidence
that the axis seems to suffer from abnormal regulation – higher
basal plasma cortisol and ACTH were found in patients com-
pared to controls (399). Leblhuber et al. examined 11 randomly
selected male HD patients with definitive diagnosis and found
higher serum levels of cortisol and reduced DHEAS compared
to healthy controls (400). Most recently, pre-motor symptomatic
HD patients significantly differed from advanced stage patients
for measures of salivary cortisol, and this was associated with
depressive symptoms (401). Interestingly, it was proposed that this
association was lost in the advanced group possibly due to“exhaus-
tion of the HPA-axis” and the prolonged exposure to elevated
cortisol levels. In a study examining both the R6/2 mouse model
and HD patients, the HPA-axis was hyperactive in R6/2 trans-
genic mice displaying advanced symptoms of the disease (402).
Baseline corticosterone concentrations were elevated in this early
onset mouse model starting at 5.5 weeks of age and this was attrib-
uted to hyperplasia of the adrenal gland, possibly arising from
pituitary dysfunction since DRD2 expression was reduced. How-
ever, as eluded to above, young R6/2 mice displaying advanced
symptoms of HD is not reflective of the wider clinical population.
Thus elevated corticosterone level at this stage of disease progres-
sion in the model is not informative for potential correlations
between HPA-axis state and early onset depression. The increased
corticosterone level in the mouse model mirrored the elevated
levels of cortisol found in urine samples of HD patients at later
stages (stage III/IV) of disease progression. There was no signif-
icant difference between stage I/II patients and controls. Shirbin
et al. have further proposed that non-depressed early stage HD
patients may have a hypoactive HPA-axis but with the develop-
ment of depression, hyperactivity of the HPA-axis occurs and
masks pathophysiology by increasing cortisol levels similar to
controls (403).
Abnormalities in the hypothalamus have long been implicated
in HD given abnormal clinical alterations in energy metabo-
lism, bodyweight, euglycemia and circadian rhythms (404–408).
Importantly, Aziz et al. have found that night-time sleep impair-
ment, likely the result of circadian alterations, correlated with
depression (409). Examination of the diurnal regulation of cor-
tisol secretion in early stage medication-free HD patients revealed
evidence of HPA-axis-hyperactivity as overall cortisol secretion
was increased, especially at specific periods such as the morn-
ing peak after awakening and during the early morning between
midnight and 4 a.m. (40). These suggested a disturbance in the
central GC feedback due to hypothalamic pathology. In a sim-
ilar study, Van Duijn et al. measured salivary cortisol in pre-
motor symptomatic, motor symptomatic, and control subjects
across six time points, focusing on the morning peak in the
first hour after awakening (410). They found that cortisol levels
were elevated in presymptomatic HD gene carriers immediately
after awakening but surprisingly no differences were observed
between symptomatic patients and controls. However, the full
period of the diurnal cycle was not examined and differences
at other times, such as in the early morning, could have gone
undetected.
The huntingtin protein is ubiquitously expressed by all cells
so it is not surprising that in HD, there is reported pathophys-
iology at all levels of the HPA-axis – hypothalamus, pituitary
and the adrenals. One approach to defining the hypothalamus
as the key structure mediating the depressive symptoms in HD is
to manipulate the extent of disease pathology and then observ-
ing its impact on the behavioral phenotype. Using a transgenic
bacterial artificial chromosome (BAC)-HD mouse model which
expresses the mutant full-length huntingtin gene and exhibits a
pro-depressive behavioral phenotype, Hult et al. found that tar-
geted inactivation of mhtt expression in hypothalamic neurons
was sufficient to prevent the pro-depressive behaviors (411). The
depressive phenotype of BACHD mice was successfully treated
with sertraline treatment suggesting that HD-related depression is
in part caused by disturbance of hypothalamic control of sero-
tonergic tone. Also, BACHD mice do not develop deficits of
hippocampal cell proliferation or neurogenesis (agreeing with the
human PM data mentioned earlier). That is definitive evidence
that hippocampal pathology alone does not cause depression in
HD which is in contrast to its perceived role in MDD pathology.
Using the R6/1 mouse model of HD which has a much milder
disease progression compared to the R6/2, our group found that
depression-like phenotypes (measured by the forced-swim and
novelty-suppressed feeding tests) appeared in pre-motor symp-
tomatic female R6/1 mice but not males or wild-types (398).
The behavioral phenotype was initially correlated to changes in
the expression levels of 5-HT receptors in the hippocampus and
cortex. However, subsequently, we reported that hyperactivity
of the HPA-axis was selectively observed in pre-motor sympto-
matic female mice but not males (412). This preclinical evidence
implies that HPA-axis dysfunction is indeed more represented
in female patients and thus, they may require special attention
regarding diagnosis and treatment. Interestingly, although the
female-specific dysregulation manifested as a sustained elevation
of post-stress corticosterone levels, we found no differences in
GR or CRF gene expression levels in the R6/1 hypothalamus.
Instead, in vivo and in vitro evidence pointed to pathological reg-
ulation of corticosterone synthesis and secretion by the adrenal
glands. Therefore, at least in the R6/1 transgenic model, adrenal
pathology (despite the absence of adrenal hyperplasia) appears to
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precede hypothalamus pathology. Despite the mutant huntingtin
protein and polyglutamine inclusions being readily detected in the
adrenal gland (413), the physiological consequence of peripheral
pathology which could possibly modulate the central neurologi-
cal symptoms is often overlooked (414). Adrenal dysfunction can
be gaged in HD patients using the DEX suppression test or the
combinatorial DEX-CRH/ACTH stimulation tests, more typically
used to diagnose Cushing’s syndrome or Addison’s disease. Phar-
macological treatments targeting an overactive HPA-axis can then
be applied such as mifepristone, a GR antagonist (415), which to
the best of our knowledge has not been examined in either HD
patients or rodent models.
MOLECULAR PATHOLOGY OF THE HYPOTHALAMUS IN HD
Having discussed the physiological pathology of the hypothalamus
as key to HPA-axis dysfunction and the depressive symptoms, this
section will examine the molecular pathologies described of the
hypothalamus. We noted that there is a somewhat limited body
of human data expounding the molecular pathology potentially
underlying the range of HD symptoms. However, studies of the
various preclinical models of HD have been tremendously use-
ful in uncovering novel molecular perturbations. These should be
used to facilitate further clinical studies to confirm the pathologies
predicted to occur in the human HD brain.
Structural and functional imaging studies have shown that
hypothalamic aberrations are palpable even in early stage, pro-
dromal HD gene carriers (362, 416, 417). Post mortem studies
have found increased CRH mRNA expression in the PVN of HD
patients (418), as well as reductions of orexin (419), oxytocin, and
AVP expressing neurons (420). In contrast, a similar change in
hypothalamic CRH gene expression is not evident in pre-motor
symptomatic R6/1 HD mice (412). The possibility that this occurs
as the disease progresses with age has yet to be explored. Many
of the hypothalamic hormones and peptides have been shown to
have modulatory roles on the HPA-axis such as oxytocin (421) and
could potentially be applied clinically with little side effects as an
adjunct or prophylaxis. Oxytocin has been shown to interact with
estrogen receptor-β in the PVN to modulate both HPA-axis activ-
ity and depression-related behaviors of rats (422). Further studies
could explore oxytocin as a candidate mediating the observed
sex-specific nature of depressive behaviors in HD rodent mod-
els. This is especially pertinent as the hypothalamus also regulates
the hypothalamic–pituitary–gonadal (HPG) axis, which has been
shown to be dysregulated in HD patients (383, 423, 424) and
rodent models (424–426). Recently, we reported that despite no
changes to estrogen receptor expression in the hypothalamus, an
acute injection of the estrogen receptor-β agonist diarylpropioni-
trile was sufficient to ameliorate the depression-like behavior of
female R6/1 HD mice (427), suggesting that treatments based on
modulation of estrogen signaling may prove to be fruitful.
Closely related to the altered diurnal rhythm of cortisol (see
Dopaminergic Dysregulation is Central to HPA-Axis Pathophysi-
ology in PD) are disturbances of diurnal patterns of activity and
sleep–wake cycles that are reported by the early stages of HD
(428, 429). These disease features are also recapitulated across
several animal models of HD (430–434). Importantly, the distur-
bance of sleep patterns is a significant feature of major depression
too (435–437), and involves altered gene expression of multiple
neuropeptide receptors in the hypothalamus (438). The suprachi-
asmatic nucleus in the hypothalamus regulates circadian rhythms,
which are significantly impacted upon in major depression [see
reviews by Lall et al. (439) and McCarthy and Welsh (440)].
There is very limited evidence of hypothalamic molecular pathol-
ogy based on the study of human HD brains. One post mortem
cohort study found that immunoreactivity for vasoactive intesti-
nal polypeptide (VIP) and arginine vasopressin (AVP) was sig-
nificantly reduced in HD brains (441). The molecular pathol-
ogy was selective as immunoreactivity for melotonin receptors
was unchanged. A decrease in VIP expression is also observed
in cortical layers of the human HD brain (442) and is repro-
duced in a mouse model of HD (443). Cell death is unlikely
to be the primary cause of pathology in this brain region. The
evidence suggests a disruption of neuronal signaling since the
number of AVP-positive neurons remaining unchanged despite
the reduced AVP mRNA levels and immunoreactivity (418). It
is worth considering the prospect of using CSF vasopressin lev-
els as a predictor of HD hypothalamic pathology since it has
been used as an AD biomarker (444). In terms of treatment,
agomelatine (a dual agonist of the melatonin receptors) is effec-
tive in treating MDD (445). This compound has yet to be trialed
in HD patients, but recent preclinical evidence from a study of
the 3-NP lesion model of HD is positive by rescuing weight loss,
motor and cognitive deficits (446). Future research should com-
prise of testing this drug in genetic models of HD, as well as
studying the effect of agomelatine treatment on related circadian
disturbances.
The huntingtin protein is a key regulator of feeding behavior
and body weight through its direct interaction with huntingtin-
associated protein (HAP-1) (447, 448). A disturbance of feeding
signals originating from the hypothalamus could account for
weight loss in HD. Changes in appetite are frequently associated
with depressed mood (449, 450) but a study specifically examin-
ing appetite levels has not been conducted of the HD population.
It would be also interesting to gather clinical data of weight loss
and attempt to differentiate between depressed and non-depressed
HD patients based on changes in body weights. Disrupting the
expression of HAP-1 alone is sufficient to cause HD-like hypo-
thalamic degeneration in mice (451). On that basis, one could
hypothesize that hypothalamic pathology in HD partly reflects a
disruption of the normal interaction between the huntingtin and
HAP-1 proteins. However, it was established early on that the HAP-
1 protein interacts with the huntingtin protein in a manner that
is independent of the abnormal polyglutamine tract and does not
contribute to the molecular pathology as observed in transgenic
HD mice (452).
In post mortem HD brains, mRNA levels of prohormone con-
vertases are decreased in the hypothalamus (453). Prohormone
convertases are essential for the regulation of neuropeptides such
as NPY (454) but their expression and activity have not been a
subject of active investigation in preclinical models of HD. Studies
have shown that NPY-positive interneurons are a distinct pop-
ulation of cells, which are specifically impacted upon by disease
processes (455). Therefore, despite the lack of knowledge of how
NPY modulates the disease processes, it is not surprising that there
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is evidence of NPY exerting beneficial effects in preclinical rodent
models by slowing the progression of disease symptoms including
minimizing weight loss (456, 457).
In considering possible reasons for the somewhat limited body
of information regarding molecular pathology of the hypothal-
amus, we suggest that it could either be due to greater focus on
collecting physiological measurements of hypothalamic/HPA-axis
dysfunction, or there is an investigative imbalance which sees the
research focused on other brain regions (e.g., striatum, cortex,
hippocampus). We are not understating the importance of estab-
lishing the physiological pathology of the hypothalamus since it
is more applicable in the clinical setting, being used as disease
biomarkers or measurements of treatment efficacy. Admittedly,
markers of neuronal molecular pathology are not practical in the
clinical setting with the exception of perhaps brain biopsies. How-
ever, such information is extremely useful, even vital, when using
preclinical models to understand the precise timeline of disease
progression. It would then be possible to reconstruct a precise dis-
ease timeline for distinct brain regions and signaling pathways.
Armed with that, it is not unimaginable that future treatment
strategies target multiple pathologies in multiple brain regions to
address the wide spectrum of HD symptoms.
GLUCOCORTICOID INFLUENCE ON HD SYMPTOMS AND PATHOLOGY
Given the evidence of a hyperactive HPA-axis and upregulation
of hypothalamic CRH gene expression, combined with the higher
risk of depression, it is important to determine and understand
how increased GC levels directly impact on HD pathology and
symptom progression. Unfortunately, our present understanding
of GC regulation of mutant htt protein processing or accumulation
of protein aggregates is poor due to the absence of comprehensive
in vitro studies of how GCs regulate htt gene transcription, protein
translation, or the rate of nuclear inclusion accumulation. Thus,
due to the lack of any clear evidence that GC signaling modifies
the molecular basis for this disease, we will instead discuss the
available clinical and preclinical evidence that stress constitutes a
significant non-genetic modifier of HD.
However, we will start by highlighting two studies that have
shed some light into the direct regulation of mhtt-mediated mol-
ecular pathology by GC signaling. A study conducted more than a
decade ago reported reduced survival of non-neuronal cell cultures
following the disruption of GC signaling due to decreased polyg-
lutamine protein solubility and increased rate of nuclear aggregate
formation (458). Follow-up studies are required to demonstrate
that neuronal and non-neuronal cells process mutant htt protein
differently to the normal protein, and this is directly influenced
by GC levels. There have also not been any preclinical studies that
have characterized the impact of stress on these measures of cel-
lular pathology. However, by applying the GR agonist DEX to fly
and mouse models of HD and reporting that this reduced pro-
tein aggregate load, one recent study has demonstrated the in vivo
impact of GC regulation on disease pathology (459). There is still
tremendous opportunity for future studies to more closely exam-
ine how htt (mRNA and protein) is regulated by GC signaling,
how the kinetics of this is changed in HD, and how elevated GC
signaling due to stress or HPA-axis dysfunction might contribute
to depression and other disease symptoms.
By comparison, there have been numerous clinical studies
investigating the genetic (460–463) and environmental (e.g., diet)
modifiers (464) of the age-of-onset of HD. Strangely, there has
yet to be a specific study of the potential impact of life-long stress
or major traumatic life events on age-of-onset. Despite the con-
vincing evidence of the higher risk for depression and HPA-axis
dysfunction, it is odd that life-long stress or major traumatic expe-
riences have not been considered to be disease modifiers since
these are both significant factors for MDD. Focusing on preclinical
models of HD, studies investigating stress as a potential modi-
fier of disease symptoms are few in comparison to studies of diet
(465–468) or environmental modifiers (469–473). The first study,
which specifically set out to examine the impact of stress on HD
symptoms, imposed daily restraint stress on asymptomatic young
adult (8 weeks old) R6/1 transgenic mice until motor symptoms
developed (474). Chronic restraint stress did not have a nega-
tive impact on motor symptoms, anhedonic behavior (saccharine
preference), or short-term working memory (Y-maze). It was dis-
cussed that the lack of an observable effect on behavioral measures
was due to the extended period of restraint stress and mice could
be acclimatizing to the stressful experience. In order to address this
possibility, Mo et al. directly manipulated GC levels by adminis-
tering corticosterone through drinking water in order to induce
sustained high levels of corticosterone in HD mice (475). They
found that this experimental approach was sufficient to induce
anhedonic behavior and diminished olfactory sensitivity in female
mice after just 2 weeks, but the HD mice were not more sensitive to
GC treatment. Interestingly, emergence of corticosterone-induced
cognitive deficits was accelerated in male, but not female, HD mice
compared to wild-type controls (474). While it is not surprising
that corticosterone influences cognitive performance given that
the high levels of GR expression in the hippocampus, the sex-
specific manner in which this was observed is highly novel. This
needs to be further investigated in a clinical population to deter-
mine if male HD patients develop cognitive deficits at an earlier
age and if this translates to more severe cognitive deficits over the
course of the disease. By comparison, corticosterone administra-
tion did not alter the age of onset of motor symptoms in HD
mice, replicating the absence of impact by restraint stress and fur-
ther indicating a specific influence of GCs on cognitive aspects of
HD. Future work should investigate depression-related behavioral
measures in preclinical HD models. The findings of these initial
studies should also guide the design of future clinical studies inves-
tigating stress as a non-genetic modifier of disease symptoms by
focusing on cognitive measures (and possibly depression) instead
of motor symptoms.
One way by which increased GC signaling could modulate
the cognitive deficits described in the R6/1transgenic model is
through its regulation of BDNF/TrkB signaling. BDNF/TrkB sig-
naling is essential for hippocampal synaptic plasticity and has a
well-established role in cognition (476, 477). BDNF/TrkB levels
are also posited to be involved with depression pathology and are
diminished in post mortem studies (albeit based on suicide cases
and having not been replicated by independent research groups)
(478–481). mRNA and protein levels of both BDNF and TrkB
receptor are reduced in post-mortem HD brain tissue (482–484).
The link between BDNF/TrkB signaling, GCs, and depression has
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been thoroughly explored in rodent models and given much atten-
tion since stressors such as forced immobilization and social defeat
consistently decrease BDNF/TrkB levels in the hippocampus, cor-
tical and subcortical brain regions of rodents (485, 486). Corti-
costerone treatment recapitulates the stress-induced reductions of
BDNF and TrkB expression in the hippocampus and frontal cor-
tex in rodents (487–491). As a demonstration of the important
role of TrkB in regulating GC influence on cognitive processes,
stress-induced spatial memory impairments can be blocked by
7,8-dihydroxyflavone, a selective TrkB agonist (492). Interestingly,
Mo et al. reported that the modulation of R6/1 cognitive deficits
by corticosterone was associated with a specific increase in the
levels of phosphorylated TrkB protein in the hippocampus with
no changes to BDNF or GR expression (474). The selective TrkB
agonist 7,8-dihydroxyflavone has been found to benefit motor
symptoms and survival of the N171-82Q mouse model of HD
(493) but studies of this compound as a therapeutic for cogni-
tive deficits, depressive behavior or HPA-axis pathology have yet
to be conducted. Besides TrkB, BDNF also signals down-stream
through its low affinity p75NTR receptor which is increased in
the caudate of HD brains (484). That observation is not too dis-
similar from studies of the hippocampal tissue from suicided post
mortem brains (480, 494). Therefore, it is also possible that ele-
vated GC signaling (stress) impacts on HD cognitive and affective
symptoms due to an imbalance of the TrkB/p75NTR ratio. Future
post mortem studies to quantify phospho-TrkB and p75NTR lev-
els should be conducted to determine if their relative ratios may
be predictive of the severity of cognitive deficits, patients’ life-
long burden of stress, depressed/non-depressed status or HPA-axis
dysfunction.
Closely related to BDNF/TrkB signaling, antidepressant com-
pounds such as the SSRI sertraline have been successfully used to
alleviate the pro-depressive behavioral phenotype of several trans-
genic mouse models of HD in a BDNF-dependent manner (398,
472, 495–497). To-date, no study has examined whether the behav-
ioral effects involve modulating hypothalamic and/or HPA-axis
function by SSRIs. However, despite an initial promise of SSRIs
possibly benefiting motor and cognitive symptoms based on pre-
clinical evidence (389), the clinical evidence thus far indicates no
significant benefit on any symptom apart from mood (385, 386).
Interestingly, physical exercise, a potent stimulant of BDNF gene
expression in the hippocampus (498), shows benefits on HD symp-
toms in preclinical (471, 472, 499) and clinical studies (500, 501).
It is possible to quantify BDNF levels from patient blood samples,
so future studies could consider attempting to correlate changes
in peripheral levels of BDNF with exercise therapy to improve-
ments in cognitive deficits and mood. Other parameters worthy
of consideration include potential normalization of diurnal cor-
tisol patterns, improvement of sleep, and normalization of DEX
response. Preclinical studies conducted in parallel could also inves-
tigate whether exercise interventions have the capacity to correct
HD-related HPA-axis dysfunction.
DISCUSSION
Alzheimer’s diseases, PD, and HD are neurodegenerative disor-
ders mostly associated with their distinctive motor symptoms (PD
and HD) or cognitive deficits (AD and HD). However, there is
FIGURE 1 | Broad schematic of gene×environmental interactions
potentially causative of the greater incidence of co-morbid depression
in AD, PD, and HD.
increasing evidence that the lesser-studied peripheral aspects of
these conditions do exert significant influence on the severity of
symptoms, the rate of disease progression, and thus the patient’s
overall quality of life. In this review, we have focused on depression
as a common co-morbidity of AD, PD, and HD. We discussed the
higher prevalence of depression in all three diseases as a function
of HPA-axis pathology by drawing upon clinical and preclinical
data (see Figure 1 for broad schematic). In this review, we were
struck by the lack of clinical evidence from large patient cohorts
with respect to HPA-axis pathology. Detailed understanding of
how stress and GCs impact on the molecular and cellular aspects
of pathology is lacking for some. While data from cohort stud-
ies supported the greater incidence of depression, there was little
by way of definitive functional assessments of the HPA-axis (pre-
sented as Tables 1–3). It is essential that such studies be performed
in future so that the robustness of findings from smaller clinical
studies can be independently assessed. Gathering data from larger
cohorts would also enable investigators to examine for potential
subtle differences in HPA-axis pathology specific to the disease in
question. This is especially interesting given the complex nature
of certain diseases, such as AD, which are linked with multiple
genetic risk factors as each may contribute a different genetic
load in dictating the extent of HPA-axis pathophysiology. While
large cohort studies are expensive and require intensive invest-
ments of time and resources, they are necessary if the field is to
bridge the current gap between the clinical and preclinical stud-
ies. Preclinical data inform us that specific pathologies may exist
at distinct segments of the HPA-axis but ultimately, confirma-
tion can only be gleaned from clinical evidence. The ability to
match up preclinical and clinical data is powerful as it provides
the impetus to further study the molecular aspects of disease using
preclinical models. Furthermore, researchers will be able to use
those preclinical models to assess therapeutic interventions with
greater confidence for reproducing the beneficial effects in clinical
environments.
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Hypothalamic–pituitary–adrenal-axis dysregulation, just as
depression diagnosis, can often be identified in the early stages of
the diseases we elected to discuss. We propose that in addition to
advocating for mandated monitoring for signs of clinical depres-
sion, regular clinical assessments of HPA-axis regulation should be
considered. With growing awareness of depression as a diagnostic
symptom (as in the case of HD), it is perhaps time to explore the
potential of indicators of HPA-axis activity as independent disease
biomarkers. Given the relative effectiveness of various pharmaco-
logical compounds and physical therapies to treat both depression
and HPA-axis pathology, there is an opportunity to intervene at
the earliest stages of disease. To effectively slow the rate of disease
progression and to maintain a certain quality of life for the patient
is highly attractive and definitely one worth considering.
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